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Antiresorptive   agents   have   revolutionized   cancer   and   osteoporosis   therapy.[1]  
Following   the   introduction   of   non-­nitrogen-­containing   etidronate   and   clodronate  
into   clinical   practice,   nitrogen-­containing   bisphosphonates   (BPs)   pamidronate,  
alendronate,   ibandronate,   risedronate,   and   zoledronate   soon   followed.[2]  
Nitrogen-­containing  BPs  possess  a  higher  clinical  potency,  better  binding  affinities  
to  bone,  and  different  mechanisms  of  action  in  the  target  cell  compared  with  their  
non-­nitrogen-­containing   predecessors.[3,   4]   BPs   are   inorganic   pyrophosphates  
which  incorporate  into  bone  to  deactivate  osteoclasts  located  on  bone  surfaces.[5]  
Denosumab,  a  fully  human  monoclonal  antibody,  was  approved  by  the  Food  and  
Drug   Administration   in   2010   with   the   ability   to   inhibit   the   binding   of   receptor  
activator  of  nuclear  factor  kappa-­B  ligand  (RANKL)  to  receptor  activator  of  nuclear  
factor  kappa-­B  (RANK).[5,  6]  It  was  recognized  that  densoumab  did  not  present  
with   evidence   of   sustained   binding   to   bone   surfaces,   a   benefit   for   patients  
concerned  with  the  long  half-­life  of  BPs.[5]  
  
1.2  Medication-­related  osteonecrosis  of  the  jaw  
Antiresorptive  medications  such  as  BPs  and  the  RANKL-­inhibitor  denosumab  are  
used   for   the   treatment   of   osteoporosis,   Paget’s   disease,   hypercalcemia   of  
malignancy,   multiple   myeloma,   and   metastatic   bone   disease   from   oncologic  
tumors.[7]   Medication-­related   osteonecrosis   of   the   jaw   (MRONJ)   is   a   serious  
complication   of   these   frequently   prescribed   medications   which   has   profound  
implications  for  the  fields  of  oral  and  maxillofacial  surgery,  oral  medicine,  dentistry,  
oncology,  pharmacology,  and  oral  biology.  A  diagnosis  of  MRONJ,  according  to  
the  American  Association  of  Oral  and  Maxillofacial  Surgeons  (AAOMS),  includes  
current  or  previous  treatment  with  antiresorptives  or  anti-­angiogenic  agents,  visible  
exposed  bone  or  bone  that  can  be  probed  through  an  intraoral  or  extraoral  fistula  
in   the  maxillofacial   region   persisting   for  more   than   8  weeks,   and   no   history   of  
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radiation   therapy   or   obvious   metastatic   disease   to   the   jaws.[7]   Treatment   of  
MRONJ   is  difficult   and  costly,   and  disease  sequela   can   include  pain,   infection,  
inability  to  eat,  extraoral  fistula,  and  pathologic  fracture,  all  of  which  significantly  
impact  the  quality  of  life  for  patients  (Figure  1).[8,  9]    
  
Although   the   first   case   of   bisphosphonate-­related   osteonecrosis   of   the   jaw  
(BRONJ)  was  reported  over  a  decade  ago[10],   the  pathogenesis  of  the  disease  
remains  unclear.  Consequently,   there   is  no  unified   recommended  prevention  or  
treatment   protocol.  Denosumab-­related   osteonecrosis   of   the   jaw   (DRONJ)  was  
more  recently  reported  with  the  RANKL-­inhibiting  fully  human  monoclonal  antibody  
(Figure   2).[5,   11]   The   prevalence   of   BRONJ   ranges   from   3%   to   as   high   as  
27.5%[12]   in   patients   receiving   nitrogen-­containing   BPs   for   metastatic   bone  
malignancy  and  multiple  myeloma,  with  a  mean  incidence  of  7%[13]  depending  on  
cumulative  dose.[14,  15]  The   risk   for  DRONJ  among  cancer  patients  has  been  
considered  by   the  AAOMS   to  be  comparable   to   the   risk   for  BRONJ   in  patients  
exposed   to   zoledronate[7],   while   others   estimate   a   higher   occurrence   rate   for  
DRONJ  compared  to  BRONJ.[16,  17]  Over  2800  articles  can  be  currently  found  
on  the  Pubmed  database  investigating  this  phenomenon.  Newer  cases  are  being  
reported  with  other  medication  classes  including  tyrosine  kinase  inhibitors  (TKIs),  
vascular   endothelial   growth   factor   (VEGF)   inhibitors,   and  mechanistic   target   of  
rapamycin  (mTOR)  inhibitors[18-­21],  so  clinicians  and  researchers  may  expect  to  
see  an  increase  in  the  incidence  of  MRONJ.  
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Figure   1.   Intraoral   bone   exposure   and   extroral   fistula   in   patients   with  
medication-­related  osteonecrosis  of  the  jaw.  A:  Stage  2;;  B  and  C:  Stage  3.  
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Figure  2.  Therapies  associated  with  medication-­related  osteonecrosis  of  the  
jaw   according   to   the   American   Association   of   Oral   and   Maxillofacial  
Surgeons  2014  Update.[7]  TKIs  =  tyrosine  kinase  inhibitors;;  VEGF  =  vascular  
endothelial  growth  factor;;  mTOR  =  mechanistic  target  of  rapamycin;;  MRONJ  




Various  mechanisms  have  been  proposed  for  how  antiresorptives  may  cause  such  
a  site-­specific  osteonecrosis.  The  jaw  bone  may  be  particularly  sensitive  to  BPs  
since   it   demonstrates   up   to   a   20-­fold   higher   turnover   rate   compared   to   other  
skeletal  sites.[22-­24]  If  high  BP  content  resulted  in  generalized  bone  necrosis,  then  
evidence  of   toxicity   throughout   the  skeleton  would  be  expected   in  proportion   to  
bone   turnover.[25]   Site-­dependent   differences   in   matrix   composition,  
biomechanical  properties,  osteoclastic  bone  resorption,  and  skeletal  pathobiology  
may   also   contribute   to   the   unique   localisation   of   MRONJ   exclusively   to   the  
jaws.[26,  27]  Proposed  hypotheses   that  attempt   to  explain   the  pathogenesis  of  
MRONJ   include   altered   bone   remodelling   or   over-­suppression   of   bone  
resorption[28-­30],   angiogenesis   inhibition[31],   sustained   microtrauma[32],  
suppression  of  innate  or  acquired  immunity[33],  suppression  of  local  immunity[34-­
36],   vitamin   D   deficiency[37],   soft   tissue   toxicity[25],   and   inflammation   and  
infection.[38-­40]  These  models  for  the  etiology  of  MRONJ  have  been  discussed  
theoretically,  however  confirming  the  exact  process  is  still  in  progress.    
  
1.4  Extrinsic  and  intrinsic  pathways  of  necrosis  
As  the  name  implies,  osteonecrosis  of  the  jaw  (ONJ)  is  assumed  to  be  primarily  a  
bone  condition.  How  precisely  ONJ  is  initiated  remains  controversial.  It  is  unknown  
whether   the   lesion   originates   within   the   bone   or   from   the  mucosa;;   historically,  
speculation  has  been  focused  on  the  bone.[41]  The  main  hypothesis  is  that  ONJ  
is  caused  by  an  over-­suppression  of  bone  turnover  by  BPs.[29,  30]  Yet,  this  theory  
	   13	  
does  not  explain  why  ONJ  occurs  almost  exclusively   in   the  maxillofacial  region,  
and  it  is  also  unclear  why  it  should  present  with  loss  of  the  soft  tissue  covering  of  
the  jaw  bones  as  the  primary  clinical  feature.[25]  Several  definitions  for  ONJ  have  
been  proposed,  and  with  the  exception  of  the  stage  0  non-­exposed  bone  variant,  
stage  1,  2,  and  3  MRONJ  all  involve  a  breach  in  the  oral  mucosa  leading  to  the  
exposure  of  maxillary  or  mandibular  bone.[7]  Although  the  bulk  of  research  thus  
far   has   involved   the   effect   of   BPs   on   bone—an   “inside-­out”   theory—it   is   also  
compelling   to   investigate   how   the   adverse   effects   of   BPs   in   circulation   and/or  
released  from  the  bone  could   influence  the  viability  of   the  soft   tissues   to  play  a  
critical   role   in   the   initiation   of   MRONJ—an   “outside-­in”   hypothesis.[41]   Some  
authors  propose  that  soft  tissues  exposed  to  BPs  could  trigger  osteolysis,  which  
could  be  combined  with  or  exacerabated  by  the  effects  of  BPs  released  from  the  
bone  on  the  soft  tissues.[42]    
  
1.5  Research  aims  
The  main  goal  of  this  doctoral  project  was  to  provide  a  more  profound  picture  of  
how   BPs   and   denosumab   could   influence   the   expression   patterns   of   human  
gingival   fibroblasts   (HGFs)   and   participating   cells   in   MRONJ.   Retrospective  
histologic  and   radiographic  examinations  provide   the  possibility   to  correlate   the  
altered  bone  structure  with  different  disease  variants  and  degree  of  antiresorptive  
exposure.  
  
1.6  Real-­time  in  vitro  assays  of  HGFs  
One  of   the  proposed  mechanisms  of  MRONJ   involves   the  soft   tissue   toxicity  of  
HGF   cells,   leading   to   delayed   wound   healing   after   epithelial   damage   and  
secondary   infection.[43]  However,   the   role  of   soft   tissue   in   the  pathogenesis  of  
MRONJ   is   particularly   not   well   defined.   Gingival   cells   have   been   previously  
analysed   in   vitro   at   selected   fixed   time   points[44,   45],   but   so   far   no   real-­time  
analysis  has  been  performed  to  observe  how  the  cells  are  affected  in  growth  and  
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wound  repair.  Furthermore,  the  effects  of  denosumab  on  this  cell  type  have  not  yet  
been  published  at  present.  
  
This   project   attempted   to   clarify   the   pathogenesis   of   MRONJ   due   to   the  
medication-­related  damage  of  the  surrounding  soft  tissue  by  investigating  the  role  
of  antiresorptives  to  induce  or  inhibit  cell  death  and  inflammation  in  HGFs  that  may  
influence   angiogenesis   and  wound   healing   in   response   to  BP   and   denosumab  
therapy   (Figure   3).   We   investigated   whether   this   effect   was   medication   dose-­
dependent,  and  whether  it  could  be  augmented  by  a  bacterial  challenge  simulated  
by  lipopolysaccharide  (LPS)  and/or  a  co-­culture  with  a  mononuclear  cell  line.    
  
The   investigation   was   carried   out   on   an   in   vitro   HGF   cell   culture  model.   Four  
different   BPs   of   varying   potencies   (alendronate,   ibandronate,   zoledronate,   and  
clodronate)  and  denosumab  at  low,  middle,  and  high  concentrations  were  used  to  
determine   the   Effective   Concentration.   The   readout   was   cell   adhesion,  
proliferation,  and  cell  death  of  HGFs  as  well  as  in  response  to  infection  and  a  co-­
culture   with   monocytes   via   the   xCELLigence   Real-­Time   Cell   Analyzer   (ACEA  
Biosciences  Inc.,  San  Diego,  USA;;  Figure  4).  This  system  provided  a  non-­invasive  
approach   to   assess   cellular   growth,   morphologic   changes,   viability,   migration,  
cytotoxicity,   and   cell   death   on   a   cell   culture   level   via   electrical   impedance  
measurements   in   real-­time.[46]  Depending  on   the  proliferation  curves  of  HGFs,  
optimal  examination  times  were  defined  for  analyses  to  be  performed.  A  further  
co-­culture  of  peripheral  blood  mononuclear  cells  with  HGFs  helped  to  clarify  the  
interaction  between  cells  in  the  presence  of  BPs,  denosumab,  and  LPS  to  allow  
for  observation  of  additional  immunologic  reactions.  The  THP-­1  human  monocytic  
cell  line  was  chosen  as  a  historically  reliable  monocyte/macrophage  model  due  to  
similar  morphologic  and  functional  properties,  including  differentiation  markers.[47,  
48]  
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Additionally,   gingival   fibroblasts   have   been   demonstrated   to   interact   with  
immunologic  and  tissue  repair  functions  by  reacting  to  and  secreting  mediators  or  
vascular  and  tissue  growth  factors.  Most  of  these  findings  were  linked  to  research  
on  periodontitis.[49,  50]  A  quantitative  real-­time  polymerase  chain  reaction  (qRT-­
PCR)   assay   was   performed   for   pro-­inflammatory,   angiogenic,   and  
osteogenic/osteoclastogenic  gene  expression.  An  enzyme-­linked  immunosorbent  
assay   (ELISA)   of   the   co-­culture  medium   in   the   presence  and  absence  of  BPs,  
denosumab,   and   LPS   was   performed   for   further   inflammatory   and   angiogenic  




Figure  3.  Real-­time  in  vitro  assays  of  human  gingival  fibroblasts  exposed  to  
antiresorptives  with  and  without  the  addition  of  LPS  and  THP-­1  
mononuclear  cells  in  co-­culture.  LPS  =  lipopolysaccharide;;  BP  =  
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bisphosphonate;;  DN  =  denosumab;;  HGF  =  human  gingival  fibroblasts;;  IL  =  
interleukin;;  TNF-­α  =  tumor  necrosis  factor  alpha;;  VEGF  =  vascular  
endothelial  growth  factor;;  RANKL  =  Receptor  activator  of  nuclear  factor  
kappa-­Β  ligand;;  OPG  =  osteoprotegerin.  
  
  
RANKL  is  a  surface-­associated  ligand  expressed  on  hematopoietic  bone  marrow  
stromal  cells,  osteoblasts,  and  B  and  T  lymphocytes[51,  52],  which  is  responsible  
for   activating   its   corresponding   receptor   RANK   on   mononucleated   osteoclast  
precursor  cells  of  the  monocyte/macrophage  lineage.[53]  This  consequently  leads  
to   their   differentiation   into   multinucleated   bone-­resorbing   osteoclasts.[54]  
Osteoprotegerin   (OPG)   is   a   soluble   decoy   receptor   for   RANKL   that   inhibits   its  
interaction  with  RANK,   thereby   preventing   osteoclastogenesis.[55]   These   three  
molecules   are   important   regulators   of   bone   modeling,   and   alteration   of   the  
RANKL/OPG   expression   ratio   has   been   demonstrated   clinically   in   periodontal  
disease.[56,  57]    
  
Cytokines  such  as  tumor  necrosis  factor  alpha  (TNF-­α),  interleukin  1  beta  (IL-­1β),  
and  interleukin  (IL)-­6  are  closely  linked  to  the  occurrence  of  inflammation  due  to  
their  regulation  of  cycloxygenase-­2  (COX-­2)  expression,  resulting  in  the  production  
of   key   inflammatory  mediators.[58]	  TNF-­α   is   produced   by  many   cell   types   and  
works   synergistically   with   IL-­1   to   stimulate   the   production   of   chemokines   and  
mediators  which  sustain  the  inflammatory  response,  including  prostaglandins  and  
lytic   enzymes.[59,   60]   The   loss   of   fibroblasts   that   occurs   during   infection   with  
periodontal  pathogens  is  also  mediated  in  part  by  TNF.[61]  IL-­1β  is  an  important  
element   of   the   inflammatory   response   which   directly   regulates   several   genes  
expressed  during  inflammation  and  also  has  been  demonstrated  to  play  a  role  in  
osteoclastic  bone  resorption.[62-­64]  One  of  the  major  functions  of  IL-­6  is  in  B  cell  
differentiation   in   the   adaptive   immune   response.[65]   B   cells   are   activated   and  
transformed   into   plasma   cells,   which   produce   antibodies   against   bacterial  
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antigens.   IL-­8   is  produced  by  epithelial  cells,  and   is   responsible   for  chemotaxis  
and   angiogenesis   by   recruiting   neutrophil   migration   and   increasing   monocyte  
adhesion  in  the  blood  vessels.[66]  VEGF  is  a  signal  protein  produced  by  many  cell  
types  that  stimulates  the  formation  of  blood  vessels.[50]  
  
  
Figure  4.  xCELLigence  Real-­Time  Cell  Analyzer  system  (ACEA  Biosciences),  
a  non-­invasive  approach  to  assess  cellular  growth,  morphologic  changes,  
viability,  migration,   cytotoxicity,   and   cell   death   on   a   cell   culture   level   via  
electrical  impedance  measurements  in  real-­time.  
  
  
1.7  Histologic  examination    
In   addition   to   in   vitro   studies   on   soft   tissue   damage,   the   examination   of   bone  
affected  by  and  exposed  to  antiresorptive  medications   is  essential   to   identifying  
the  pathophysiology  of   the  MRONJ  disease  process.  This  project  characterized  
histopathologic  features  of  MRONJ  by  examining  and  comparing  bone  biopsies  of  
BRONJ,  DRONJ,  and  Mixed  ONJ  (necrosis  with  both  BP  and  denosumab)  with  
bone  exposed   to  antiresorptive  medications   (BP  and  both  BP  and  denosumab)  
and   other   bone   samples   of   inflammatory   (primary   osteoporosis),   infectious  
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(secondary  chronic  osteomyelitis),  and  necrotic  jaw  diseases  (osteoradionecrosis),  
as  well  as  bone  from  healthy  patients  (removed  during  dental  extractions).  
  
This  project  aimed  to  contribute  the  following  information  currently  missing  from  
the   literature:   the   comparison   of   histologic   changes   including   bone  
histomorphometrics  in  tissue  composition,  the  composition  of  immune  competent  
cells   and   cytokine   profiles   in   infectious   environments,   and   evidence   of   the  
remodeling   of   bone   exposed   to   antiresorptive   therapy   with   no   clinical   signs   of  
MRONJ.  Micro-­computed  tomography  (CT)  was  utilitized  to  analyze  the  relation  of  
bone   and   medullary   space   in   response   to   antiresorptive   treatments.   DRONJ  
patients   in  previous  studies  were  often   initially  exposed  to  other  antiresorptives,  
perhaps  confounding  the  influence  of  any  distinct  agent.  With  this  patient  cohort  
we  were   able   to   identify   features   of   denosumab-­specific   osteonecrosis   without  
influence  from  previous  BP  therapy.  
  
1.8  Radiographic  evaluation  
MRONJ   demonstrates   a  mixed   pattern   of   necrosis   and   infection   clinically.   The  
clinical  examination  does  not  usually  show  the  full  extent  and  severity  of  necrotic  
sites  beneath  the  mucosa.  In  principle,  the  diagnosis  is  made  based  on  both  the  
clinical  and  radiographic  examination.  However,  diagnostic  radiographic  findings  
are  not  universally  agreed  upon  since  imaging  findings  are  non-­specific  and  can  
also  be  found  in  other  conditions  such  as  osteomyelitis,  osteoradionecrosis,  cancer  
metastasis,   and   Paget´s   disease.   Thus   far,   imaging   findings   have   not   been  
incorporated   into   the   diagnostic   criteria,   nor   have   radiographic   features   been  
included   for   the   classification   of   disease   stage.   Their   findings   corroborate   the  
evaluation   of   the   course,   extent,   and   progression   of   the   disease.   Panoramic  
radiography,   CT,   magnetic   resonance   imaging   (MRI),   and   scintigraphy   are  
valuable  imaging  modalities  that  confirm  and  augment  clinical  findings  by  revealing  
different  aspects  of  bone  involvement.    
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The  goal  of  this  project  was  to  characterize  radiographic  signs  of  necrosis  in  
BRONJ,  DRONJ,  and  Mixed  ONJ  using  various  imaging  techniques  and  to  
evaluate  the  correlation  of  the  clinical  presentation  with  imaging  findings.  
Diagnostic  radiographic  files  of  MRONJ  patients  were  analysed  retrospectively  
for  radiographic  signs  before  and  after  disease  management,  including  surgical  
operation  when  needed.  Imaging  findings  were  compared  with  histologic  results  
to  confirm  the  analysis  of  the  effect  on  bone  tissues.  Radiographic  changes  such  
as  increased  bone  density/sclerosis  could  be  an  indirect  indication  of  bone  
remodeling,  allowing  for  the  corroboration  of  the  macroscopic  appearance  to  
microscopic  activity  in  histologic  samples.  Radiologic  findings  were  also  
evaluated  for  possible  predictive  parameters  that  may  be  prognostic  for  disease  
development  and  clinical  course.    
  
  
2  Materials  and  Methods    
Part  I  Real-­time  in  vitro  assays  of  HGFs  
  
2.1  Cell  culture  with  HGFs  and  THP-­1  cells  
Commercially   available   HGF   cells   (Provitro,   Berlin,   Germany)   were   cultured   in  
HGF  medium  (Provitro,  Berlin,  Germany)  containing  10%  heat-­inactivated  fetal  calf  
serum   (FCS,  Provitro,  Berlin,  Germany),  50.00  ng/mL  amphotericin  B   (Provitro,  
Berlin,   Germany),   and   50   μg/mL   gentamicin   (Provitro,   Berlin,   Germany).   Cells  
were   cultured   in   75   cm2   flasks   at   37°C   in   a   humidified   incubator   at   5%   CO2.  
Subculturing  was  performed  when  cell  confluence  exceeded  75%.  Human  gingival  
fibroblast  cells  were  plated  at  a  density  of  3.0  x  105  per  75  cm2  culture  flask,  and  
culture  medium  was  changed  every  48  to  72  hours.  
  
THP-­1   cells   (ATCC,  Manassas,   VA,  USA)  were   cultured   in  RPMI-­1640   culture  
medium  (GIBCO,  Darmstadt,  Germany)  containing  0.05  mM  2-­mercaptoethanol,  
10%  heat-­inactivated  FCS  (Sigma-­Aldrich,  Munich,  Germany),  100  U/mL  penicillin/  
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streptomycin  (Lonza,  Cologne,  Germany),  and  50  mg/  mL  fungicide  (Biochrom  AG,  
Berlin,  Germany).  Cells  were   cultured   in  75   cm2   flasks  at   37°C   in  a  humidified  
incubator  at  5%  CO2.  Subculturing  was  performed  when  cell  density  exceeded  5  
to  7  x  106.  THP-­1  cells  were  plated  at  a  density  of  1.2  x  106  per  75  cm2  culture  
flask,  and  culture  medium  was  added  or  replaced  in  a  new  passage  every  96  to  
120  hours.  
  
2.2  Live  monitoring  with  the  xCELLigence  system    
The  xCELLigence  DP  system  (ACEA  Biosciences  Inc.,  San  Diego,  USA)  was  used  
for  continuous  monitoring  of  cell  adherence.  Using  xCELLigence  E-­plates  16  and  
E-­plates   16   VIEW   (ACEA   Biosciences   Inc.,   San   Diego,   USA),   changes   of  
impedance  for  cells  attached  to  the  detector  plates  were  measured  at  20  mV  every  
15  minutes  and  calculated  as  the  dimensionless  parameter  Cell  Index  (CI):  
  
CI  =  [Zi-­Z0]/15  
[Zi:  impedance  at  an  individual  experimental  point;;  Z0:  background  measurement  
at  the  beginning  of  the  experiment]  
  
Background   measurements   were   performed   twice   with   50   mL   HGF   medium.  
Figures  were  displayed  with  the  Delta  Cell  Index  (DCIti),  a  standardized  calculation  
of  Cell  Index  (CIti)  using  a  constant  (delta  value)  over  time  with  standard  deviation.  
The   measured   value   was   proportional   to   the   attached   number   of   cells   to   the  
detector   plate   and   also   reflected   the   morphology   of   cells   and   quality   of   cell  
attachment.    
  
2.3  Normal  HGF  cell  growth  
Normal   HGF   cell   growth   was   measured   with   the   xCELLigence   system   using  
various   seeding   densities   (1500-­6000   cells   per   cm2)   to   determine   the   optimal  
growth  curve.  A  cell  suspension  of  100  μl  with  4000  cells  was  added  in  each  E-­
plate  well.  Growth  was  monitored  until  natural  cell  death,  and  the  appropriate  live-­
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monitoring  period  was  established.  Culture  medium  was  changed  after  48  hours  
at  the  optimum  time  of  confluence  as  confirmed  visually  by  the  E-­plate  16  VIEW  
and  simultaneous  24-­well  plate  experiments.    
  
2.4  Antiresorptives  
Zoledronate  (Sequoia  Research  Products,  Pangbourne,  UK),  ibandronate  (Sigma-­
Aldrich,   Taufkirchen,  Germany),   and   alendronate   (Sequoia  Research  Products,  
Pangbourne,  UK)  in  concentrations  of  0.5  μM,  5  μM,  and  50  μM[25,  41,  67-­71];;  
clodronate  (Sigma-­Aldrich,  Taufkirchen,  Germany)  in  concentrations  of  50  μM,  125  
μM,  and  500  μM[72];;  denosumab  in  concentrations  of  3  μg/mL,  10  μg/mL,  and  40  
μg/mL[6];;  or  a  combination  of  zoledronate  and  denosumab  in  concentrations  of  0.5  
μM    +  40  μg/mL,  5  μM    +  10  μg/mL,  and  5  μM    +  40  μg/mL  were  then  added  to  
each  E-­plate  well  containing  HGF  cells  for  experimentation  (Table  1).[73]  These  
concentrations  were  determined  by  established  experimental  concentrations  in  the  
literature  and  reported  tissue  concentrations  as  referenced  above.[45,  74]  
  






Alendronate   0.5  µM   5  µM   50µM  
Ibandronate   0.5  µM   5  µM   50µM  
Zoledronate   0.5  µM   5  µM   50µM  
Clodronate   50  µM   125  µM   500  µM  
Denosumab   3  μg/mL   10  μg/mL   40  μg/mL  
Zoledronate  +  
Denosumab  
0.5  μM    +  40  
μg/mL  
5  μM    +  10  μg/mL   5  μM    +  40  μg/mL  




Of  note,  BP  concentrations  are  conventionally  reported  as  molar  units  of  µM,  while  
the  newer  medication  denosumab  is  recommended  to  be  reported  as  mass  units  
of  µg/mL.[75]  Equivalent  concentrations  of   these  medications  can  be  calculated  
using  the  following  formula:  
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µg/mL  x  1,000  mL/L  x  1  µmole/([molar  mass]  µg)  =  µmol/L  =  µM  
  
2.5  LPS  experiments  
For  experiments  with  LPS,  various  concentrations  of  Porphyromonas  gingivalis  (P.  
gingivalis)   LPS   (InvivoGen,   San   Diego,   USA)   were   tested   according   to  
concentrations   established   in   the   literature.[76,   77]   LPS   was   added   at   a  
concentration  of  3  μg/mL  or  10  μg/mL  to  each  E-­plate  well  with  the  applicable  BP,  
which   accompanied   the   medium   change   at   48   hours.   LPS   10   μg/mL   was  
determined  to  be  the  optimal  concentration.  
  
2.6  Co-­culture  experiments  with  THP-­1  cells  
Viability   of   a   co-­culture   was   established   by   initially   confirming   the   successful  
growth  of  HGFs  in  RPMI  medium.  BPs  and  LPS  10  μg/mL  in  100  μl  RPMI  medium  
were  added  at  48  hours  as  described  above.  Concurrently,  50  μl  of  THP-­1  cell  
suspension  optimized  at  a  density  of  40,000  cells[78,  79]  and  LPS  10  μg/mL  were  
added  to  each  well  of  an  E-­plate  insert  (ACEA  Biosciences  Inc.,  San  Diego,  USA)  
and  loaded  onto  the  E-­plate.  The  E-­plate  insert  allowed  for  the  two  different  cell  
populations  to  be  separated  by  a  0.4  μm  pore  size  membrane.  This  pore  size  was  
tested   to   confirm   the   absence   of   cell   migration,   enabling   the   measurement   of  
indirect  cell-­to-­cell  interactions  in  the  co-­culture.  
  
2.7  Real-­time  monitoring  of  cell  adherence    
Live  monitoring  of  adherence/differentiation  was  performed  for  a  mimimum  of  216  
hours.   In   each   experiment,   the   inflexion   point   of   cell   adherence/cell   death  was  
measured,   indicating   the   beginning   of   cell   death   predominance   over   cell  
adherence.  The  mean  of   the   inflexion  point  of  each  antiresorptive  concentration  
and  control  was  calculated  from  live-­monitoring  data.  Intraindividual  differences  of  
inflexion   points   of   cell   adherence/death   to   the  maximum   control   value   in   each  
experiment   set   were   also   calculated   to   exclude   bias   in   individual   experiments.  
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Each   experiment   was   performed   in   duplicates   and   repeated   at   least   twice   to  
confirm  reproducibility  of  results.    
  
2.8  24-­well  plate  confirmation  experiments  
Experiments   performed   on   the   xCELLigence   system   were   confirmed   by  
simultaneous   experiments   in   24-­well   plates   (Costar,   Kaiserslautern,   Germany)  
using   established   concentrations   (Figure   5).   Three   sets   of   experiments   were  
performed   analogous   to   the   xCELLigence   experiments:   antiresorptives   only,  
antiresorptives  and  LPS,  and  a  co-­culture  with  antiresorptives,  LPS,  and  THP-­1  
cells.  Two  plates  (one  with  a  scratch  assay  and  one  without)  were  used  for  each  
experiment  set  to  assess  the  effect  on  wound  healing.  Once  normal  growth  and  
optimal  cell  densities  were  confirmed  in  preliminary  experiments,  1  mL  of  HGF  cell  
suspension  at  an  experimentally  established  density  of  25,000  cells  were  added  
to  each  well  of  the  24-­well  plate.    
  
When  the  cell  layer  was  fully  confluent  at  48  hours,  the  scratch  assay  wells  were  
scraped  with  a  200  μl  pipette  tip,  and  antiresorptives  were  added  to  each  well  in  
both  the  scratch  and  non-­scratch  plates  accompanying  a  medium  change.  In  LPS  
experiments,  P.  gingivalis  LPS  10  μg/mL  was  added  with  antiresorptives  during  
the  medium  change  at  48  hours.  For  co-­culture  experiments,  a  200  μl  THP-­1  cell  
suspension  with   an   experimentally   established   density   of   250,000   cells   and  P.  
gingivalis  LPS  10  μg/mL  were  added  into  a  Greiner  ThinCert™  (Greiner  Bio-­One,  
Frickenhausen,   Germany),   which   was   placed   individually   into   each   well.   The  
Greiner  insert  allowed  for  the  two  different  cell  populations  to  be  separated  by  a  
0.4   μm   pore   size  membrane,   enabling   the  measurement   of   indirect   cell-­to-­cell  
interactions  in  the  co-­culture  and  collection  of  the  supernatant  for  protein  analysis.  
Experiments  were  run  for  9  days  for  the  antiresorptive  and  LPS  experiments,  and  
6  days  for   the  co-­culture  with  no  further  medium  change.  Each  experiment  was  
performed   in  duplicates  and  repeated  at   least   twice   to  confirm  reproducibility  of  
results.  
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Figure   5.   Layout   of   antiresorptive   concentrations   in   24-­well   plate  
experiments.  Clo  =  clodronate;;  Iban  =  ibandronate;;  Zol  =  zoledronate;;  Alen  
=  alendronate;;  Den  =  denosumab;;  LPS  =  lipopolysaccharide;;  Cont  =  control.  
  
  
2.9  Morphologic  analysis  by  light  microscopy    
Cells   were   monitored   and   visualized   by   inverted   light   microscopy   (Leica  
Microsystems,  Wetzlar,  Germany)  every  12-­24  hours,  and  digital   images  of   the  
cells  were  collected  for  the  documentation  of  cell  growth,  scratch  healing,  and  cell  
death.  Greiner  co-­culture  inserts  were  stained  with  hematoxylin  after  both  24  and  
96  hours  and  visualized  by  light  microscopy  and  photographed.  
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To  confirm  and  visualize  live-­monitored  effects  of  antiresorptives  on  HGF  viability,  
a   time-­dependent   Live/Dead   staining   (Life   Technologies,   Eugene,   USA)   was  
performed   after   96   hours   of   incubation.   Membrane-­permeant   calcein   (2   mM)  
cleaved  by  esterase   in   living  cells   yielded  cytoplasmic  green   fluorescence,  and  
membrane-­impermeant   ethidium   homodimer-­1   (4  mM)   labeled   nucleic   acids   of  
membrane-­compromised  cells  with  red  fluorescence.  Cells  were  washed  twice  in  
phosphate-­buffered  saline  (PBS)  and  incubated  with  100  μL  staining  solution  for  
15  minutes  at  room  temperature.  Labeled  cells  were  visualized  using  an  Observer  
Z1   fluorescence   microscope   (Zeiss,   Oberkochen,   Germany)   and   AxioVs40  
V4.8.2.0  software,  and  digital  images  were  collected.  
  
2.11  Scanning  electron  microscopy  
Cell  adherence  was  confirmed  by  scanning  electron  microscopy  (DSM  982  Gemini  
by  Zeiss,  Oberkochem,  Germany).  Cells  (initially  seeded  at  a  density  of  50,000)  in  
12-­well  plates  (Costar,  Kaiserslautern,  Germany)  were  fixated  with  glutaraldehyde  
(2.5%)  and  washed  with  ethanol  (30%-­100%  for  2  minutes).  Plates  were  then  CO2  
dried   (critical   point   dryer  BAL-­TEC  CPD  030,  Balzers,   Lichtenstein),   fixed   onto  
Thermanox   slices   (Plano,  Wetzlar,   Germany)   using   Leit-­Tabs   (Plano,  Wetzlar,  
Germany),  and  coated  with  gold  (40  nm,  Sputter  Coater  S150  B,  Edwards,  North  
Walsham,  UK).  
  
2.12  Gene  expression  analysis  
HGF  cells  were  collected  from  a  separate  run  of  24-­well  plate  experiments  after  24  
hours  of  antiresorptive  treatment  with  and  without  LPS.  Wells  were  washed  with  
PBS,  incubated  with  80  μL  trypsin  for  5  minutes,  and  centrifuged.  The  supernatant  
was   removed   and   100   μL   RA1   Buffer   with   2   μL   TCEP   (NucleoSpin   RNA   XS,  
Macherey-­Nagel,  Düren,  Germany)  was  added  to  each  sample,  which  was  frozen  
at  -­80°C  until  assayed.  Highly  pure  RNA  was  eluted  from  the  samples  using  the  
NucleoSpin  RNA  XS   (Macherey-­Nagel,  Düren,  Germany)  and  measured  with  a  
Qubit  3.0  Fluorometer  (Thermo  Fisher  Scientific,  Waltham,  USA).  First-­stranded  
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cDNA  for  a  PCR  template  was  synthesized  using  70-­116  ng/μL  (over  1μg  total)  of  
total  RNA  using  an  oligo-­dT  primer  under  conditions  indicated  by  the  manufacturer  
(Advantage  RT-­for-­PCR  Kit;;  Clontech,  Heidelberg,  Germany).  Specific  primers  for  
TNF-­α,   OPG,   RANKL,   IL-­8,   and   glyceraldehyde-­3-­phosphate   dehydrogenase  
(GAPDH)  were  obtained  from  the  LightCycler  Primer  Set  (Search  LC,  Heidelberg,  
Germany).  Each  cDNA  was  amplified  in  the  presence  of  SYBR  Green  Master  Mix.  
The   quantification   of  GAPDH  encoding  messenger  RNA   (mRNA)   by   qRT-­PCR  
served  as  an  internal  control  for  each  cDNA  sample.  The  conditions  for  PCR  were  
1  x  (95°C,  10  min)  denaturation,  40  x  (95°C,  10  sec;;  68°C,  10  sec;;  72°C,  16  sec)  
amplification,  1  x  (95°C,  1  sec;;  58°C,  10  sec;;  95°C,  1  sec)  melting  curve,  and  1  x  
(40°C,  30  sec)  cooling.  Gene  expression  analysis  using  was  performed  by  qRT-­
PCR  using  the  Light  Cycler  2.0  System  (Roche,  Basel,  Switzerland).  
  
2.13  Protein  expression  analysis    
Cell  culture  medium  was  collected  from  the  24-­well  plate  co-­culture  experiments  
at  24  and  96  hours  and  frozen  at  -­80°C  until  assayed.  The  production  of   IL-­1β,  
VEGF,  and  IL-­6  was  measured  in  the  cell  culture  supernatants  using  the  Human  
IL-­1β  Quantikine  ELISA  Immunoassay  (R&D  Systems,  Minneapolis,  USA)  at  24  
hours,   the   Human   VEGF   Quantikine   ELISA   Immunoassay   (R&D   Systems,  
Minneapolis,   USA)   at   24   hours,   and   a   Human   IL-­6   Quantikine   ELISA  
Immunoassay   (R&D   Systems,   Minneapolis,   USA)   at   96   hours   following  
manufacturer   instructions.   The   absorbance   values   of   IL-­1β,   VEGF,   and   IL-­6  
secretion  were  measured  at  wavelengths  of  450  nm,  with  corrections  of  540  nm  or  
570  nm.  Protein  expression  analysis  was  performed  by  the  ELISA  reader  (BioTek,  
Winooski,  USA).  
  
2.14  Statistical  analysis    
Statistical   analyses   were   performed   using   RTCA   Software   1.2.1   (ACEA  
Biosciences  Inc.,  San  Diego,  USA),  and  the  standard  deviation  was  stated  in  curve  
progression.   Additional   data   analysis   was   performed   with   JMP   10.0.2   (SAS  
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Institute,  Cary,  NC,  USA).  The  primary  outcomes  were  the  inflexion  points  of  cell  
adherence/death  in  the  xCELLigence  experiments  and  calculated  concentrations  
and  relative  gene  expression  in  the  ELISA  and  qRT-­PCR  analyses,  respectively.  
Intraindividual  differences  of   inflexion  points   to   the   individual  experiment  control  
were  also  calculated  to  account  for  individual  experiment  bias.  A  paired  Student’s  
t-­test  was  performed,  and  the  Tukey-­Kramer  method  was  used  to  confirm  results  
and  account  for  experiment-­wise  error.  A  p  value  <  .05  was  considered  significant.  
  
  
Part  II  Histologic  examination  
  
2.15  Patient  population/histologic  bone  samples  
Following  informed  consent  and  approval  from  the  institutional  ethical  committee,  
surgical  biopsies  were  obtained  from  the  following  patient  groups:  
  
1.   BRONJ  
2.   DRONJ  
3.   Mixed  ONJ  (osteonecrosis  due  to  both  BP  and  denosumab)  
4.   Healthy  bone  exposed  to  BP  (BP-­exposed)  
5.   Healthy  bone  exposed  to  BP  and  denosumab  (BP-­DN  exposed)  
6.   Osteoradionecrosis  of  the  jaw  (ORN)  
7.   Secondary  chronic  osteomyelitis  (OM)  
8.   Osteoporosis  
9.   Healthy  bone  of  the  jaw  
10.  Necrotic  bone  secondary  to  other  chemotherapies  
11.  Transplanted  bone  
  
Bone   samples   were   analyzed   in   a   retrospective   histologic   study   and   medical  
record   review  and  compared   to  both   the  Healthy  and  Osteoporosis  group.  The  
osteoporosis  groups  also  served  as  a  reliable  control  since  both  cancer  patients  
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(breast   and   prostate)   and   osteoporosis   patients   frequently   begin   antiresorptive  
therapy  in  an  osteopenic  state.  The  study  population  was  composed  of  all  patients  
presenting  for  evaluation  and  management  of  the  above-­mentioned  jaw  diseases  
between  October  2010  and  January  2016.  To  be  included  in  the  study,  patients  
had  to  have  at  least  one  follow-­up  visit  evaluated  and  managed  in  the  Department  
of  Oral  and  Maxillofacial  Surgery,  University  Hospital  Tuebingen,  Germany,  and  
were  excluded  if  the  total  observation  period  was  less  than  two  months.  According  
to  the  recommendation  of  the  AAOMS,  the  diagnosis  of  MRONJ  was  confirmed  if  
all  the  following  criteria  were  satisfied:  1.  current  or  previous  treatment  with  a  BP  
or   denosumab;;   2.   exposed   necrotic   bone   in   the   maxillofacial   region   that   has  
persisted  for  more  than  8  weeks;;  3.  no  history  of  radiation  therapy  or  metastasis  
to   the   jaws.[7]   Patient   characteristics   collected   included   patient   demographics,  
primary   disease   diagnosis,   antiresorptive   regimen   and   schedule,   duration   of  
therapy,  concurrent  primary  disease  therapy,  time  to  onset  of  MRONJ,  association  
of  onset  with  dental  procedure,  AAOMS  stage,  presence  of  pain,  treatment  type,  
follow-­up   course,   and   management   outcomes   (healed   versus   not   healed).  
Complete  healing  was  defined  as  no  exposed  or  probeable  bone  with  no  pain.  
  
Bone   biopsies   were   washed   in   saline   solution,   and   immediately   fixed   in   10%  
buffered   formalin.   Bone   samples   were   decalcified   with   Usedecalc   (MEDITE,  
Orlando,  USA),  embedded  in  paraffin,  and  microsectioned  at  3  µm  thickness.  The  
microsections  were  then  stained  with  hematoxylin  and  eosin  (H&E)  to  examine  for  
signs  of  infection  and  cellular  composition,  RANKL  and  OPG  for  bone  remodelling  
activity,   tartrate-­resistant   acid   phosphatase   (TRAP)   for   osteoclast   activation,  
toluidine   blue   for   bony   structural   composition   and   architecture,   and   CD14   and  
CD68   for   the   presence   of   monocytes   and   macrophagic   cells.   Selected   bone  
samples   were   additionally   analyzed   by   micro-­CT   scanning   (Siemens   Inveon  
MicroCT  System,  Siemens,  Germany).   Images  were   reconstructed   at   a   27   µm  
voxel   size   and   visualized   using   the   Inveon   Research   Workplace   Software   by  
Siemens.  
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2.16  Data  collection  
Histochemical   stains  were   visualized  under  an   inverted   light  microscope   (Leica  
Microsystems,   Wetzlar,   Germany).   The   following   data   were   collected   for   H&E  
stain:   presence   of   infection   (0-­1),   pseudoepithelial   changes   (0-­1),   granulation  
tissue  (0-­1),  fibrous  tissue  (0-­1),  and  scallopped  resorption  (0-­1);;  RANKL:  RANKL  
stain   positivity   (0-­8);;   TRAP:   TRAP   stain   positivity   (0-­8),   the   number   of   TRAP-­
positive   multinucleated   cells   with   over   three   nuclei   per   cell;;   OPG:   OPG   stain  
positivity  (0-­8);;  Toluidine  blue:  number  of  osteocyte  lacunae  per  area,  organization  
level  (0-­2),  presence  of  reversal  lines  (0-­2),  and  presence  of  Haversian  canals  (0-­
2);;  CD14:  CD14  positivity   (0-­8);;  CD68:  CD68  positivity   (0-­8).  Positivity  of  stains  
were  assessed  by  the  9  point  (0-­8)  Allred  Score.[80,  81]  Five  different  fields  were  
analyzed   at   20x   magnification   for   each   individual   stain,   and   the   mean   was  
calculated.  Individual  cells  per  area  were  quantified  manually  for  each  specimen  
with   Image   J   software   (National   Institutes   of   Health,   Bethesda,   USA).   Digital  
images  of  the  stained  sections  were  collected  using  an  inverted  light  microscope  
(Leica  Microsystems,  Wetzlar,  Germany).  Necrotic  bone  samples   from  BRONJ,  
DRONJ,   and   Mixed   ONJ   biopsies   were   further   categorized   into   sequestrum,  
border   bone,   and   newly   formed   bone   and   separately   analyzed   to   account   for  
location   bias.   Samples   labeled   as   sequestrum   were   omitted   from   the  
immunohistochemical   evaluation   of   living   cells   including   RANKL,   OPG,   TRAP,  
CD14,  and  CD68.  Analysis  of  micro-­CTs  was  completed  in  69  bone  samples,  and  
the  percent  of  medullary  space  to  bone  was  measured  in  addition  to  the  width  of  
bone   trabeculae   using   Ginkgo   CADx   Dicom   Viewer   (MetaEmotion   Healthcare,  
Valladolid,   Spain).   Histologic   and   histomorphometric   analyses   were   performed  
blind  by   the   reviewer,  without   knowledge  of   the  clinical   features  of   the  patients  
corresponding  to  individual  biopsies.  
  
2.17  Statistical  analysis  
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Descriptive   statistics   were   used   to   report   patient   characteristics.   Groups   were  
compared  using  analysis  of  variance  (ANOVA)  with  p  <  .05  indicating  significance.  
All  statistical  analyses  were  performed  with  STATA  version  14.0  (Statacorp  LLC,  
College  Station,  USA).  
  
  
Part  III  Radiographic  evaluation  
  
2.18  Radiographic  evaluation  
Electronic  medical  records  of  adult  cancer  and  osteoporosis  patients  with  at  least  
two   diagnostic   panoramic   radiographs/clinic   visits   diagnosed   with   BRONJ,  
DRONJ,  or  Mixed  ONJ  were  reviewed.  Patient  characteristics  collected  included  
patient   demographics,   primary   disease   diagnosis,   antiresorptive   regimen   and  
schedule,  duration  of  therapy,  concurrent  primary  disease  therapy,  time  to  onset  
of  MRONJ,  association  of  onset  with  dental  procedure,  AAOMS  stage,  presence  
of   pain,   treatment   type   (operative   versus   non-­operative),   follow-­up   course,   and  
management  outcomes  (healed  versus  not  healed).  Complete  healing  was  defined  
as  no  exposed  or  probeable  bone  with  no  pain.  
  
Radiographs  were  obtained  for  each  patient  based  on  clinical  need,  and  findings  
were  confirmed  by   two  oral   specialists   (oral  and  maxillofacial   surgeon  and  oral  
medicine   specialist)   and   one   radiologist   in   consensus.   Panoramic   radiograph,  
cone   beam   computed   tomography   (CBCT),   CT,   scintigraphy,   and   MRI   were  
evaluated  for  common  radiographic  signs  of  osteonecrosis  including  sequestrum,  
bony  fistula,  bone  fracture,  persistent  extraction  sockets,  erosion  of  cortical  bone,  
sclerosis  of  cortical  bone,  sclerosis  of  cancellous  bone,  periosteal  sclerosis,  inferior  
alveolar   nerve   (IAN)   canal   involvement,   thickened   lamina   dura,  maxillary   sinus  
involvement,  activity  of  scintigraphy,  and  cervical  lymph  node  involvement  (Table  
2).[82-­84]    
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   Imaging  
modality  
           
Radiographic  sign   Panoramic  
radiograph  
CBCT   CT   MRI   Scintigraphy  
Sequestrum   X   X   X        
Bony  fistula   X   X   X        
Bone  fracture   X   X   X        
Persistent  extraction  sockets   X   X   X        
Erosion  of  cortical  bone   X   X   X        
Sclerosis  of  cortical  bone   X   X   X        
Sclerosis  of  cancellous  bone   X   X   X        
Periosteal  sclerosis   X   X   X        
IAN  canal  involvement   X   X           
Thickened  lamina  dura   X              
Maxillary  sinus  involvement      X   X        
Positive  scintigraphy  activity               X  
Cervical  lymph  node    
involvement  
      X   X     
  
Table   2.   Commonly   reported   radiographic   signs   of   medication-­related  
osteonecrosis  of  the  jaw  and  their  optimal  imaging  modality.  CBCT  =  cone  
beam  computed  tomography;;  CT  =  computed  tomography;;  MRI  =  magnetic  
resonance  imaging;;  IAN  =  inferior  alveolar  nerve.  
  
  
The  detectability  of  MRONJ   findings  using   the  various   imaging   techniques  was  
calculated  according  to  a  modified  formula  proposed  by  Stockmann  et  al.  [85]:  
  
%  detectability  =     number  of  positive  findings  with  a  particular  imaging  method  
                 number  of  total  detected  findings    
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(This  excluded  imaging  modality-­specific  findings  such  as  thickened  lamina  dura,  
scintigraphy  activity,  lymph  node  involvement,  etc.)    
  
Descriptive   statistics   were   used   to   report   patient   characteristics.   Radiographic  
changes  over   time  were  analyzed  with   linear  regression,  with  p  <  .05   indicating  
significance.   All   statistical   analyses   were   performed   with   STATA   version   14.0  




Part  I  Real-­time  in  vitro  assays  
  
3.1  Real-­time  analyses  of  cell  adherence    
Live  monitoring   indicated   a   similar   initial   differentiation   of   antiresorptive-­treated  
and  untreated  HGF  cells   for  approximately  60  hours   (Figure  6),   followed  by  an  
individual  inflexion  point  of  adherence/cell  death.  The  inflexion  point  for  the  control  
group  was  observed  after  90.4  ±  90.4  hours.  Nitrogen-­containing  BPs  at  50  µM  
concentrations  exhibited  early  inflexion  points  at  64.0  (alendronate)  to  66.0  hours  
(zoledronate),   with   later   inflexion   points   for   denosumab   (69.5   hours),   the  
combination  of  zoledronate  and  denosumab  (70.0  hours),  and  the  non-­nitrogen-­
containing   BP   clodronate   (78.0   hours;;   Table   3).   Differences   to   control   were  
significant  with  50  µM  alendronate  (64.0  ±  1.0  hours).  Intraindividual  differences  to  
the  control   in  each  experiment  set  also  exhibited  a  significance  to  the  individual  
experiment  control  at    concentrations  of  50  µM  for  zoledronate  (-­22.5  ±  31.8  hours),  
alendronate  (-­27.7  ±  28.3  hours),  and  ibandronate  (-­22.0  ±  31.1  hours),  as  well  for  
the  combination  of  5  µM  zoledronate  +  10  µg/mL  denosumab  (20.3  ±  17.6  hours).  
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Figure  6.  Real-­time  monitoring  of  human  gingival  fibroblast  cell  adherence  
after   confluence   and   exposure   to   antiresorptive   medications   at   various  
concentrations.  Cell  curve  describes  the  mean  values  of  cell  impedance  and  
standard  deviation  up  to  190  hours  of  observation  for  the  adherence  curves  
of  controls  and  (A)  zoledronate  and  alendronate  at  concentrations  of  0.5  µM,  
5  µM,  and  50  µM  (B)  clondronate  at  concentrations  of  50  µM,  125  µM,  and  500  
µM   and   ibandronate   at   concentrations   of   0.5   µM,   5   µM,   and   50   µM,   (C)  
denosumab   at   concentrations   of   3   µg/mL,   10   µg/mL,   and   40   µg/mL   and  
combination   of   zoledronate   and   denosumab   at   concentrations   of  
zoledronate  5  µM  +  denosumab    40  µg/mL,  zoledronate  0.5  µM  +  denosumab  
40  µg/mL,  and  zoledronate  5  µM  +  denosumab  10  µg/mL.  Curve  interruption  
















inflexion  points  of  cell  
p-­
value  





Zoledronate              
50  µM   66.0  ±  4.2        -­22.5  ±  31.8   <  .05  
5  µM   81.5  ±  21.9      -­2.0  ±  14.1       
0.5  µM   87.5  ±  30.4        4.0  ±  5.6  h     
Alendronate              
50  µM   64.0  ±  1.0     <  .05   -­27.7  ±  28.3   <  .05  
5  µM   87.0  ±  29.7        4.0  ±  5.6     
0.5  µM   87.0  ±  29.7        4.0  ±  5.6     
Ibandronate              
50  µM   66.0  ±  0.0        -­22.0  ±  31.1     <  .05  
5  µM   88.0  ±  31.1      0.0  ±  0.0     
0.5  µM   88.0  ±  31.1      0.0  ±  0.0     
Clodronate              
500  µM   78.0  ±  6.9        -­10.0  ±  14.1     
125  µM   88.0  ±  31.1      0.0  ±  0.0     
50  µM   88.0  ±  31.1      0.0  ±  0.0     
Denosumab              
40  µg/ml   69.5  ±  0.7      0.0  ±  0.0     
10  µg/ml   69.5  ±  0.7      0.0  ±  0.0     
3  µg/ml   69.5  ±  0.7      0.0  ±  0.0     
Zoledronate  +  
Denosumab  
           
5  µM  +  40  
µg/mL  
70.0  ±  1.0      -­12.33  ±  21.3     
0.5  µM  +  40  
µg/mL  
82.3  ±  22.3      0.0  ±  0.0     
5  µM  +  10  
µg/mL  
102.7  ±  4.7      20.3  ±  17.6   <  .05  
Control     90.4  ±  90.4           
Table   3.   Inflexion   points   of   cell   adherence/cell   death   and   intraindividual  
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3.2  HGFs  exposed  to  LPS  
For  HGFs   treated  with  both  antiresorptive  medications  and  P.  gingivalis  LPS,  a  
similar  initial  differentiation  of  antiresorptive-­treated  and  untreated  HGF  cells  was  
observed  for  approximately  60  hours  (Figure  7),  followed  by  an  individual  inflexion  
point   of   adherence/cell   death.   The   inflexion   point   for   the   control   group   was  
observed  after  125.3  ±  44.2  hours,  and  the  control  group  with  LPS  at  105.2  ±  12.0    
hours.  Nitrogen-­containing  BPs  at  50  µM  concentrations  exhibited  early  inflexion  
points  at  63.0  (zoledronate)  to  78.0  hours  (ibandronate),  with  later  inflexion  points  
for   the   non-­nitrogen  BP   clodronate   (89.0   hours)   and   both   denosumab   and   the  
combination   of   zoledronate   and   denosumab   (both   117.0   hours;;   Table   4).  
Differences  to  control  were  significant  with  50  µM  zoledronate  (63.0  ±  4.4  hours)  
and  ibandronate  (78.0  ±  18.3  hours),  as  well  as  all  concentrations  of  alendronate  
dose-­dependently.   Intraindividual   differences   of   the   inflexion   points   of   cell  
adherence/death  in  each  experiment  set  exhibited  a  significance  to  the  individual  
experiment  control  value  at  concentrations  of  50  µM  for  zoledronate  (-­93.5  ±  78.4  











Figure  7.  Real-­time  monitoring  of  human  gingival  fibroblast  cell  adherence  
after   confluence   and   exposure   to   Porphyromonas   gingivalis  
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lipopolysaccharide   10   μg/mL   and   antiresorptive   medications   at   various  
concentrations.  Cell  curve  describes  the  mean  values  of  cell  impedance  and  
standard  deviation  up  to  190  hours  of  observation  for  the  adherence  curves  
of  controls  and  (A)  zoledronate  and  alendronate  at  concentrations  of  0.5  µM,  
5  µM,  and  50  µM  (B)  clodronate  at  concentrations  of  50  µM,  125  µM,  and  500  
µM   and   ibandronate   at   concentrations   of   0.5   µM,   5   µM,   and   50   µM,   (C)  
denosumab   at   concentrations   of   3   µg/mL,   10   µg/mL,   and   40   µg/mL   and  
combination   of   zoledronate   and   denosumab   at   concentrations   of  
zoledronate  5  µM  +  denosumab    40  µg/mL,  zoledronate  0.5  µM  +  denosumab  
40  µg/mL,  and  zoledronate  5  µM  +  denosumab  10  µg/mL.  Curve  interruption  














Mean  and  standard  
deviation  of  
intraindividual  
differences  of  inflexion  





Zoledronate              
50  µM   63.0  ±  4.4     <  .05   -­93.5  ±  78.4   <  .05  
5  µM   103.0  ±  4.2      -­53.5  ±  75.6     
0.5  µM   103.5  ±  4.9        -­53.0  ±  74.9     
Alendronate              
50  µM   64.0  ±  0.0     <  .05   -­92.5  ±  79.9   <  .05  
5  µM   81.5  ±  17.6   <  .05   -­75.0  ±  97.5   <  .05  
0.5  µM   80.0  ±  15.5   <  .05     -­76.5  ±  95.4   <  .05  
Ibandronate              
50  µM   78.0  ±  18.3     <  .05   -­24.5  ±  16.2     
5  µM   113.0  ±  2.8      10.5  ±  0.7     
0.5  µM   108.5  ±  9.1      6.0  ±  7.0     
Clodronate              
500  µM   89.0  ±  2.8      -­13.5  ±  0.7     
125  µM   102.5  ±  2.1      0.0  ±  0.0     
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50  µM   103.0  ±  11.3      0.5  ±  9.1     
Denosumab              
40  µg/ml   117.0  ±  16.9      0.0  ±  0.0     
10  µg/ml   120.5  ±  12.0      3.5  ±  4.9     
3  µg/ml   117.0  ±  16.9      0.0  ±  0.0     
Zoledronate  +  
Denosumab  
           
5  µM  +  40  
µg/mL  
117.0  ±  16.9      0.0  ±  0.0     
0.5  µM  +  40  
µg/mL  
117.0  ±  16.9      0.0  ±  0.0     
5  µM  +  10  
µg/mL  
115.0  ±  19.8      -­2.0  ±  2.8     
Control  with  
LPS  
105.2  ±  12.0           
Control     125.3  ±  44.2           
Table   4.   Inflexion   points   of   cell   adherence/cell   death   and   intraindividual  
differences  to  the  control  for  antiresorptive-­  and  lipopolysaccharide-­treated  
human  gingival  fibroblast  cells.  
  
  
3.3  HGFs  in  co-­culture  
For  HGFs  treated  with  antiresorptive  medications  and  P.  gingivalis  LPS  in  a  co-­
culture   with   THP-­1   cells,   an   initial   differentiation   of   antiresorptive-­treated   and  
untreated  HGF  cells  was  observed  for  approximately  50  hours  (Figure  8),  followed  
by  an  individual  inflexion  point  of  adherence/cell  death.  The  inflexion  point  for  the  
control  group  was  observed  after  149.6  ±  8.6  hours.  Nitrogen-­containing  BPs  at  50  
µM  concentrations  exhibited  early   inflexion  points  at   57.6   (zoledronate)   to  68.0  
hours  (ibandronate),  with  later  inflexion  points  for  the  combination  of  zoledronate  
and  denosumab  (101.0  hours),  denosumab  (152.0  hours),  and  the  non-­nitrogen  
BP  clodronate  (155.0  hours;;  Table  5).  Differences  to  control  were  significant  with  
50  µM  alendronate  (57.7  ±  9.8  hours),  50  µM  ibandronate  (68.0  ±  4.2  hours),  the  
combination  of  5  µM  zoledronate  +  40  µg/mL  denosumab  (101.0  ±  67.8  hours),  
and  zoledronate  at  concentrations  of  50  µM  and  5  µM  dose-­dependently.    
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Intraindividual  differences  of  the  inflexion  points  of  cell  adherence/death  in  each  
experiment  set  exhibited  a  significance  to  the  individual  experiment  control  value  
at  concentrations  of  50  µM  for  alendronate  (-­90.0  ±  1.7  hours),  ibandronate  (-­82.5  
±  13.4  hours),  the  combination  of  5  µM  zoledronate  +  40  µg/mL  denosumab  (-­44.0  
±   62.2   hours),   and   zoledronate   at   concentrations   of   50   µM   and   5   µM   dose-­
dependently.  Lowest  bisphosphonate  concentrations  of  0.5  µM  alendronate,  40  
µg/mL  denosumab,  the  combination  of  5  µM  zoledronate  +  10  µg/mL  denosumab,  
and   all   concentrations   (dose-­dependently)   of   clodronate   continued   to   display   a  
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Figure  8.  Real-­time  monitoring  of  human  gingival  fibroblast  cell  adherence  
after   confluence   and   exposure   to   Porphyromonas   gingivalis  
lipopolysaccharide   10   μg/mL   and   antiresorptive   medications   at   various  
concentrations   in   co-­culture   with   THP-­1   cells   in   an   xCELLigence   0.4   μM  
porous  ThinCert™.  Cell  curve  describes  the  mean  values  of  cell  impedance  
and  standard  deviation  up   to  190  hours  of  observation   for   the  adherence  
curves  of  controls  and  (A)  zoledronate  and  alendronate  at  concentrations  of  
0.5  µM,  5  µM,  and  50  µM  (B)  clodronate  at  concentrations  of  50  µM,  125  µM,  
and  500  µM  and  ibandronate  at  concentrations  of  0.5  µM,  5  µM,  and  50  µM,  
(C)  denosumab  at  concentrations  of  3  µg/mL,  10  µg/mL,  and  40  µg/mL  and  
combination   of   zoledronate   and   denosumab   at   concentrations   of  
zoledronate  5  µM  +  denosumab    40  µg/mL,  zoledronate  0.5  µM  +  denosumab  
40  µg/mL,  and  zoledronate  5  µM  +  denosumab  10  µg/mL.  Curve  interruption  
is  caused  by  medium  renewal.  
  
  





















Zoledronate              
50  µM   57.6  ±  9.8     <  .05   -­90.0  ±  1.7   <  .05  
5  µM   89.3  ±  53.6   <  .05   -­58.3  ±  57.5   <  .05  
0.5  µM   131.0  ±  68.4        -­16.7  ±  62.7     
Alendronate              
50  µM   57.7  ±  9.8   <  .05   -­90.0  ±  1.7   <  .05  
5  µM   126.7  ±  65.0        -­21.0  ±  59.1     
0.5  µM   152.0  ±  7.8        4.3  ±  8.5     
Ibandronate              
50  µM   68.0  ±  4.2   <  .05   -­82.5  ±  13.4     <  .05  
5  µM   146.0  ±  2.8      -­4.5  ±  6.3     
0.5  µM   142.5  ±  2.1      -­8.0  ±  11.3     
Clodronate              
500  µM   155.0  ±  9.9        4.5  ±  0.7     
125  µM   157.0  ±  5.6      6.5  ±  3.5     
50  µM   166.0  ±  48.0      15.5  ±  38.8     
Denosumab              
40  µg/ml   152.0  ±  4.2      7.0  ±  9.9     
10  µg/ml   147.5  ±  2.1      2.5  ±  3.5     
3  µg/ml   144.5  ±  6.3      -­0.5  ±  0.7     
Zoledronate  +  
Denosumab  
           
5  µM  +  40  
µg/mL  
101.0  ±  67.8   <  .05   -­44.0  ±  62.2   <  .05  
0.5  µM  +  40  
µg/mL  
145.0  ±  5.6      0.0  ±  0.0     
5  µM  +  10  
µg/mL  
159.0  ±  25.4      14.0  ±  19.8     
Control     149.6  ±  8.6           
Table   5.   Inflexion   points   of   cell   adherence/cell   death   and   intraindividual  
differences  to  the  control  for  antiresorptive-­  and  lipopolysaccharide-­treated  
human  gingival  fibroblast  cells  in  co-­culture  with  THP-­1  cells.  
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3.4  Scratch  assay  in  24-­well  plates  
HGFs  cultured  in  24-­well  plates  were  scratched  and  exposed  to  antiresorptives  at  
the  time  point  after  confluence  (48  hours).  Delayed  wound  healing  was  observed  
between   72   to   96   hours   in   clodronate   500   µM,   ibandronate   5   µM   and   50   µM,  
alendronate  50  µM,  zoledronate  5  µM  +  denosumab  10  µg/mL,  and  zoledronate  5  
µM,  with  obvious  severe  fibroblast  cell  death  in  zoledronate  50  µM  (Figure  9).  By  
168   hours,   ibandronate   50   µM,   zoledronate   50   µM,   zoledronate   5   µM   +  
denosumab  10  µg/mL,  alendronate  50  µM  all  demonstrated  obvious  severe  cell  
death,  while  clodronate  500  µM  showed  mild  signs  of  cell  death  compared  to  the  
intact  cell  layer  of  healthy-­appearing  confluent  controls.  
  
Fibroblasts   exposed   to   P.   gingivalis   LPS   in   addition   to   antiresorptives   also  
demonstrated  further  delayed  wound  healing.  Zoledronate  50  µM  exhibited  signs  
of  cell  death  as  early  as  24  hours.  By  48  hours,  wound  healing  was  affected   in  
clodronate   500   µM,   denosumab   40   µg/mL,   ibandronate   5   µM   and   50   µM,  
zoledronate   0.5   µM   and   5   µM,   zoledronate   5   µM   +   denosumab   10   µg/mL,  
alendronate  50  µM,  with  zoledronate  50  µM  having  already  progressed  to  severe  
cell  death.  By  96  hours,  both  alendronate  50  µM  and  zoledronate  50  µM  exhibited  
severe  cell  death.  
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Figure   9.   Human   gingival   fibroblasts   exposed   to   alendronate   50   µM,  
zoledronate  50  µM,  or  control  in  24-­well  plate  scratch  assay  at  0,  96,  and  168  
hours  after  scratch  and  antiresorptive  addition.    
  
  
3.5  Non-­scratch  assay  in  24-­well  plates  
Antiresorptives  were   toxic   to  HGFs   in   the  24-­well  plate  non-­scratch  assay  even  
without   mechanical   damage   (Figure   10).   Cells   exposed   to   a   concentration   of  
zoledronate  50  µM  already  appeared  apoptotic  at  24  hours  after   the  addition  of  
antiresorptive.  By  168  hours,  ibandronate  50  µM,  zoledronate  50  µM,  zoledronate  
5  µM  +  denosumab  10  µg/mL,  and  alendronate  50  µM  all  demonstrated  obvious  
severe  cell  death.  In  24-­well  plates  exposed  to  both  antiresorptive  and  P.  gingivalis  
LPS,  zoledronate  50  µM  demonstrated  similar  early  cell  death,  with  alendronate  
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50   µM   also   appearing   apoptotic   at   96   hours.   Findings   were   analogous   to   the  
inflexion  points  of  adherence/cell  death  observed  in  xCELLigence  experiments.  
  
  
Figure  10.  Human  gingival   fibroblasts  exposed   to  alendronate  50  µM  with  
lipopolysaccharide  (LPS),  zoledronate  50  µM  with  LPS,  or  control  in  24-­well  
plates  at  0,  96,  and  168  hours  after  antiresorptive  addition.  
  
  
3.6  Analysis  of  cell  viability/cell  death  with  fluorescence  staining    
Live/Dead  staining   results  confirmed  xCELLigence  adherence  curves  at  distinct  
time   points   after   antiresorptive   addition,   consistent   with   the   inflexion   points   of  
adherence/cell  death  described  in  Table  2.  Obvious  wound  healing  effects  were  
observed  at  96  hours  after  the  addition  of  the  antiresorptive  and/or  scratch  (Figure  
11).  Fibroblasts  exposed  to  antiresorptives  demonstrated  severe  cell  death  upon  
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administration  of  zoledronate  50  µM  and  alendronate  50  µM.  HGFs  in  the  scratch  
assay   demonstrated   effects   on   wound   healing   in   the   following   concentrations:  
clodronate  500  µM,  ibandronate  5  µM  and  50  µM,  zoledronate  5  µM,  zoledronate  
5  µM  +  denosumab  10  µg/mL,  alendronate  0.5  µM  and  50  µM  with  obvious  cell  
death  in  zoledronate  50  µM.  
  
  
Figure   11.   Human   gingival   fibroblasts   exposed   to   zoledronate   50   µM   or  
control  in  a  24-­well  plate  LIVE/DEAD  assay  at  96  hours  after  antiresorptive  
addition   and   scratch.   Green   fluorescence   depicts   membrane-­permeant  
calcein  in  living  cells  and  red  fluorescence  depicts  membrane-­impermeant  
ethidium  homodimer-­1  in  compromised  cells.  
  
  
3.7  Scanning  electron  microscopy    
Scanning  electron  microscopy  of  12-­well  plates  indicated  a  confluent  HGF  layer  in  
controls  demonstrating  normal  cell  morphology  in  comparison  to  deteriorated  cell  
morphology,  a  clear  reduction  of  adherence,  and  significant  cell  death  at  96  hours  
after  the  addition  of  zoledronate  50  µM  (Figure  12).  The  disruption  of  the  confluent  
cell  layer  was  more  severe  in  the  zoledronate  50  µM  scratch  assay  compared  to  
the  non-­scratch  assay,  though  both  were  drastically  altered  compared  to  controls.  
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Figure   12.   Scanning   electron   microscopy   of   human   gingival   fibroblasts  
exposed  to  zoledronate  50  µM  and  confluent  control  cell  layer  in  6-­well  plates  




3.8  Co-­culture  insert  from  THP-­1  co-­culture  
The  Greiner  co-­culture  inserts  containing  THP-­1  cells  from  the  24-­well  plate  co-­
culture  were  stained  with  hematoxylin  and  revealed  THP-­1  cells  remaining  on  the  
floor  of   the   insert  at  24  hours  and  96  hours  after   the  addition  of  antiresorptives  
(Figure   13).   There   was   evidence   of   macrophage   differentiation   of   THP-­1   cells  
exposed  to  concentrations  of,  among  others,  alendronate  0.5  µM  and  zoledronate  
50  µM.  
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Figure   13.   Hematoxylin   staining   of   0.4   µm   porous   Greiner   inserts   with  
adherent   THP-­1   cells   and   differentiated   macrophages   exposed   to  
ibandronate   0.5   µM   at   24   hours   and   zoledronate   50   µM   at   96   hours   after  
antiresorptive  addition.  40x  magnification.  
  
  
3.9  OPG,  RANKL,  IL-­8,  and  TNF  expression  with  qRT-­PCR    
High  concentrations  of  zoledronate  (and  slightly  denosumab)  in  combination  with  
LPS  demonstrated  high  values  of  OPG  gene  expression  (zoledronate:  773  gene  
copies;;  denosumab:  6.01  gene  copies)   in  contrast   to  control  (0.28  gene  copies;;  
Figure  14).  Antiresorptives  by   themselves  did  not  affect   the  expression  of  OPG  
without  LPS.  The  expression  of  RANKL  by  HGF  was  only  slightly   influenced  by  
zoledronate  50  µM    with  LPS  (2.49  gene  copies;;  Figure  15).    
  
High   concentrations   of   zoledronate   in   the   presence   of   LPS   exhibited   elevated  
values   of   IL-­8   gene   expression   (16.9   gene   copies)   compared   to   controls   (.007  
gene  copies;;  Figure  16).  For  TNF,  zoledronate  50  µM  (and  slightly  denosumab  40  
µg/mL)   in   the   presence   of   LPS   demonstrated   elevated   gene   expression  
(zoledronate:   443  gene   copies;;   denosumab:   2.66  gene   copies;;   control:   0   gene  
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copies;;  Figure  17).  Antiresorptives  by  themselves  did  not  affect  the  expression  of  
TNF  without  the  addition  of  LPS.    
  
  
    Figure   14.   Relative   gene   expression   of   osteoprotegrin   with   and   without  
lipopolysaccharide.   LPS   =   lipopolysaccharide;;   Zol   =   zoledronate;;   Den   =  
denosumab.  
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Figure   15.   Relative   gene   expression   of   RANKL   with   and   without  
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  Figure   16.   Relative   gene   expression   of   IL-­8   with   and   without  




Figure   17.   Relative   gene   expression   of   TNF   with   and   without  




3.10  IL-­1β,  IL-­6,  and  VEGF  expression  with  ELISA    
All  antiresorptives  significantly  elevated  the  expression  of  IL-­1β  in  both  the  scratch  
and   non-­scratch   assay   in   contrast   to   control   (Figure   18),   including   the   control  
stimulated   with   LPS   in   co-­culture.   In   contrast,   IL-­6   levels   were   significantly  
decreased   in  HGFs  exposed   to   high   concentrations  of   nitrogen-­containing  BPs  
compared  to  the  control  (Figure  19).    For  VEGF,  all  antiresorptives  elevated  the  
expression  of  VEGF   in  contrast   to  control   (including   the  control   stimulated  with  
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LPS   in   co-­culture);;   this  was   statistically   significant  with   the   exception   of   higher  
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Figure   18.   IL-­1β   ELISA   with   (A)   and   without   scratch   (B).   LPS   =  
lipopolysaccharide;;  Zol  =  zoledronate;;  Aln  =  alendronate;;  Iba  =  ibandronate;;  
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Figure   19.   IL-­6   ELISA   with   (A)   and   without   scratch   (B).   LPS   =  
lipopolysaccharide;;  Zol  =  zoledronate;;  Aln  =  alendronate;;  Iba  =  ibandronate;;  
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Figure   20.   VEGF   ELISA   with   (A)   and   without   scratch   (B).   LPS   =  
lipopolysaccharide;;  Zol  =  zoledronate;;  Aln  =  alendronate;;  Iba  =  ibandronate;;  
Clo  =  clodronate;;  Den  =  denosumab.  
  
  
Part  II  Histologic  examination  
  
3.11  Patient  groups  and  histologic  bone  samples  
A  total  of  158  bone  samples  were  collected  from  107  patients  with  BRONJ  
(32/107),  DRONJ  (4/107),  Mixed  ONJ  (8/107),  bone  exposed  to  BP  (BP-­
exposed;;  24/107),  bone  exposed  to  BP  and  denosumab  (BPDN-­exposed;;  5/107),  
ORN  (10/107),  osteoporosis  (7/107),  OM  (8/107),  and  bone  from  healthy  
individuals  (9/107).  Two  patients  with  necrotic  bone  secondary  to  other  
chemotherapies  (1/107)  and  transplanted  bone  (1/107)  were  excluded  from  the  
analysis  due  to  small  patient  group  size.  Patients  in  the  osteoporosis  group  and  
DRONJ  group  were  not  previously  exposed  to  antiresorptive  therapies.  The  
majority  of  bone  samples  were  obtained  from  the  right  mandible  (n=53)  and  left  
mandible  (n=44),  with  others  from  the  left  (n=29)  and  right  maxilla  (n=21).  Of  the  
bone  biopsies  from  patients  with  BRONJ,  DRONJ,  and  Mixed  ONJ,  46  samples  
were  labelled  as  border  bone,  26  were  labelled  as  sequestrum  bone,  and  5  as  
newly  formed  bone.  
  
3.12  Antiresorptive  dosing  
The  mean  duration  of  BP  or  denosumab  therapy  was  28.08  months  (range:  1-­
181  months)  with  a  total  average  of  17.0  non-­oral  doses  (range:  1-­123  doses)  
and  7.86  oral  doses  (range:  1-­144  doses;;  Table  6).  The  BP-­exposed  and  BRONJ  
group  had  the  longest  mean  duration  of  antiresorptive  treatment  with  47.5  
months  (range:  4-­144  months)  and  44.1  months  (range:  2-­181  months),  
respectively.  The  BRONJ  (29.7  doses;;  range  1-­123  doses)  and  Mixed  ONJ  (29.4  
doses;;  range:  1-­62  doses)  groups  demonstrated  the  highest  mean  number  of  
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non-­oral  doses,  while  the  BPDN-­exposed  group  exhibited  the  longest  duration  of  




Mean  months  of  
antiresorptive  
treatment  (range)  
Mean  number  of  
non-­oral  doses  
(range)  
Mean  months  of  
oral  doses  
(range)  
BRONJ   44.1  ±  42.8  (2-­181)   29.7    ±  30.8  (1-­123)     10.5    ±  20.3  (0-­72)    
DRONJ   13.8  ±  10.7  (1-­24)   14.0    ±  11.0  (1-­25)     -­  
Mixed  ONJ   37.8  ±  23.8  (14-­77)   29.4  ±  21.5  (1-­62)     6.0  ±  14.6  (0-­42)    
BP-­
exposed  
47.5  ±  36.7  (4-­144)   25.3  ±  22.9  (1-­72)     15.5  ±  37.3  (0-­144)    
BPDN-­
exposed  
33.0  ±  26.7  (3-­54)   2.6  ±2.7  (1-­7)     18.0  ±  24.7  (0-­48)    
Table  6.  Mean  duration  and  number  of  antiresorptive  doses  for  
antiresorptive-­related  disease  groups.  BRONJ  =  bisphosphonate-­related  
osteonecrosis  of  the  jaw;;  DRONJ  =  denosumab-­related  osteonecrosis  of  
the  jaw;;  Mixed  ONJ  =  bisphosphonate  and  denosumab  osteonecrosis  of  
the  jaw;;    BP-­exposed  =  bone  exposed  to  bisphosphonates;;  BPDN-­exposed  
=  bone  exposed  to  bisphosphonates  and  denosumab.  
  
  
3.13  Clinical  characteristics  of  patients  treated  with  antiresorptives  
Patient  were  treated  with  antiresorptives  for  primary  diagnoses  of  breast  cancer  
(n=26),  prostate  cancer  (n=16),  osteoporosis  (n=17),  multiple  myeloma  (n=4),  
and  other  cancer  (n=16).  Patients  received  zoledronate  (n=49),  alendronate  
(n=14),  denosumab  (n=12),  ibandronate  (n=12),  pamidronate  (n=3),  and  
risendronate  (n=3).  A  total  of  84  patients  received  intravenous  administration  of  
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BPs,  and  24  patients  received  oral  BPs.  The  12  patients  who  received  
denosumab  were  administered  the  medication  via  subcutaneous  injection.  Out  of  
81  patients  asked  about  the  presence  of  pain,  29  patients  reported  pain  at  the  
clinical  visit.  The  onset  of  osteonecrosis  was  mostly  associated  with  dental  
extractions  (n=28)  or  pressure  sores  from  dental  prostheses  (n=15),  while  in  13  
patients  another  association  was  reported  (i.e.,  implantitis,  periodontitis,  or  
spontaneous  onset).    A  total  of  16  patients  were  classified  as  Stage  3  MRONJ,  
28  patients  as  Stage  2,  and  only  1  patient  as  Stage  1.  Complete  healing  (no  
exposed  or  probeable  bone  with  no  complaint  of  pain)  was  reported  in  29  
patients,  and  no  healing  was  observed  in  66  patients.  
  
3.14  H&E  stain  findings  
Mixed  ONJ,  ORN,  BRONJ,  and  DRONJ  exhibited  more  infectious  infiltration  
compared  to  healthy  and  osteoporosis  groups  which  had  no  signs  of  infection.  
Bone  exposed  to  BP  exhibited  the  most  pseudoepithelial  changes.  Mixed  ONJ  
and  BRONJ  exhibited  more  granulation  tissue  along  with  pseudoepitheliomatous  
hyperplasia  in  non-­necrotic  lesions.  Osteoporosis,  OM,  and  BPDN-­exposed  
exhibited  more  fibrous  tissue;;  in  the  osteoporosis  group  the  appearance  was  
more  organized.  Mixed  ONJ  and  BRONJ  also  demonstrated  more  areas  of  
scallopped  resorption.  
  
3.15  RANKL  stain  findings  
The  mean  RANKL  stain  positivity  was  highest  for  BRONJ  (2.22)  and  Mixed  ONJ  
(1.75),  and  lowest  for  BP-­exposed  (0.59),  DRONJ  (0.43),  and  Healthy  (0.53;;  
Tables  7  and  8).  This  was  statistically  significant  for  BRONJ  (p  =  .021)  when  
compared  to  the  healthy  group.    
  
3.16  TRAP  stain  findings  
The  mean  TRAP  stain  positivity  was  highest  for  Mixed  ONJ  (2.88),  BRONJ  
(2.60),  and  BP-­exposed  (1.83),  and  lowest  for  Healthy  (0.38).    This  was  
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statistically  significant  for  Mixed  ONJ  (p  =  .002),  BRONJ  (p  <  .001),  and  BP-­
exposed  (p  =  .017)  when  compared  to  the  healthy  group.  The  mean  number  of  
osteoclasts  positive  for  TRAP  stain  per  view  was  highest  for  Mixed  ONJ  (0.78)  
and  BRONJ  (0.63),  and  lowest  for  Healthy  (0.11)  and  OM  (0.011).  This  was  
statistically  significant  for  Mixed  ONJ  (p  =  .041),  BRONJ  (p  =  .034)  when  
compared  to  the  healthy  group.  
  
3.17  OPG  stain  findings  
The  mean  OPG  positivity  was  highest  for  DRONJ  (2.89)  and  Mixed  ONJ  (2.75)  
and  lowest  for  Healthy  (1.00)  and  ORN  (1.14).  
  






RANKL  Mean  Positivity  
(0-­8)  
2.22**   1.75   0.43   0.69   0.80  
TRAP  Mean  Positivity  
(0-­8)  
2.60**   2.88**   0.77   1.83**   1.40  
TRAP  Mean  Number  of  
Osteoclasts  per  View  
0.63**   0.78**   0.14   0.30   0.17  
OPG  Mean  Positivity  
(0-­8)  
1.89   2.75   2.89   2.26   1.57  
Mean  Osteocyte  
Lacunae  per  µm2  






CD14  Mean  Positivity  
(0-­8)  
2.59**   2.13   0.80   1.09   2.37  
CD68  Mean  Positivity  
(0-­8)  
4.30**   4.73**   0.97   2.21   2.06  
Mean  Percent  
Medullary  Space  to  
Bone  
13.78**   12.30**   19.69   10.40**   9.63**  
Mean  Width  of  Osteoid  
Trabeculae  (μm)  
434.81   601.71**   504.75   476.96   654.36  
Table  7.  Histologic  and  histomorphometric  findings  of  bone  samples  for  
BRONJ,  Mixed  ONJ,  DRONJ,  BP-­exposed,  and  BPDN-­exposed  groups.  **  
indicates  statistical  significance  p  <  .05  when  compared  to  Healthy  or  ***  
compared  to  Osteoporosis.  BRONJ  =  bisphosphonate-­related  
osteonecrosis  of  the  jaw;;  Mixed  ONJ  =  mixed  osteonecrosis  of  the  jaw;;  
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DRONJ  =  denosumab-­related  osteonecrosis  of  the  jaw;;  BP-­exposed  =  
bisphosphonate-­exposed  bone;;  BPDN-­exposed  =  bisphosphonate  and  
denosumab-­exposed  bone;;  RANKL  =  receptor  activator  of  nuclear  factor  




   ORN   OM   OP   Healthy  
RANKL  Mean  
Positivity  (0-­8)   0.77   0.75   1.51   0.53  
TRAP  Mean  Positivity  
(0-­8)   0.87   0.87   1.69   0.38  
TRAP  Mean  Number  of  
Osteoclasts  per  View   0.50   0.11   0.46   0.11  
OPG  Mean  Positivity  
(0-­8)   1.14   1.60   1.33   1.00  
Mean  Osteocyte  
Lacunae  per  µm2   0.00029***   0.00033   0.00041   0.00032  
CD14  Mean  Positivity  
(0-­8)   1.59   0.56   2.71**   0.69  
CD68  Mean  Positivity  
(0-­8)   2.00   1.51   2.37   0.78  
Mean  Percent  
Medullary  Space  to  
Bone   10.92**   9.03**   18.15**   28.09  
Mean  Width  of  Osteoid  
Trabeculae  (μm)   460.69   434.63   336.74   259.07  
Table  8.  Histologic  and  histomorphometric  findings  of  bone  samples  for  
ORN,  OM,  OP,  and  Healthy  groups.  **  indicates  statistical  significance  p  <  
.05  when  compared  to  Healthy  or  ***  compared  to  Osteoporosis.  ORN  =  
osteoradionecrosis;;  OM  =  secondary  osteomyelitis;;  OP  =  primary  
osteoporosis;;  RANKL  =  receptor  activator  of  nuclear  factor  kappa-­B  ligand;;  
TRAP  =  tartrate-­resistant  acid  phosphatase;;  OPG  =  osteoprotegerin.  
  
  
3.18  Toluidine  blue  stain  findings  
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DRONJ  (0.000090;;  p  =  .007;;  Figure  21),  BP-­exposed  (0.000103;;  p  =  .028),  
BPDN-­exposed  (0.000118;;  p  =  0.022),  and  ORN  (0.000050;;  p  =  0.004)  
demonstrated  statistically  significantly  fewer  osteocyte  lacunae  per  µm2  
compared  to  Osteoporosis  (0.000171;;  Figures  22  and  23).  The  blood  supply  by  
Haversian  systems  exhibited  no  significant  differences  (Figure  24).  There  was  
even  a  tendency  for  a  higher  Haversian  canal  density  in  DRONJ,  BRONJ  and  
Mixed  ONJ  sample  groups  with  intact  blood  vessels  observed.  The  bony  
structures  appeared  more  unorganized  in  MRONJ  disease  variants  with  the  
presence  of  higher  numbers  of  bony  reversal  lines  compared  to  Osteoporosis  or  
Healthy  (Figure  25).  
  
Figure  21.  Toluidine  blue  staining  of  an  outlined  area  of  bone  fragment  in  a  
patient   with   denosumab-­related   osteonecrosis   of   the   jaw   demonstrating  
20x 
DRONJ 
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Figure  22.  Toluidine  blue  staining  of  an  outlined  area  of  bone  fragment  in  an  
patient  with  osteoporosis  demonstrating  numbered  osteocyte  lacunae  with  
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Figure  23.  Number  of  osteocyte  lacunae  per  µm2  by  disease  group.  Asterisk  
indicates  significance  p  <  .05  compared  to  the  osteoporosis  group.  BRONJ  
=  bisphosphonate-­related  osteonecrosis  of  the  jaw;;  DRONJ  =  denosumab-­
related   osteonecrosis   of   the   jaw;;   ONJ   =   osteonecrosis   of   the   jaw;;   BP   =  
bisphosphonate;;  DN  =  denosumab;;  ORN  =  osteoradionecrosis.  
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Figure  24.  Hematoxylin  and  eosin  staining  of  Haversian  canal  architecture  in  
bone   samples   of   bisphosphonate-­related   necrosis   of   the   jaw   and   mixed  
necrosis   of   the   jaw   compared   to   healthy   and   osteoporosis   groups.   4x  
magnification.  BRONJ  =  bisphosphonate-­related  osteonecrosis  of  the  jaw;;  
ONJ  =  osteonecrosis  of  the  jaw.  
4x 4x 
4x 
BRONJ Mixed ONJ 
Healthy Osteoporosis 
4x 
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Figure   25.   Toluidine   blue   staining   of   disorganized   bone   remodeling   in  
bisphosphonate-­   and   denosumab-­related   osteonecrosis   of   the   jaw  
compared  to  healthy  and  osteoporosis  disease  groups.  4x  magnification.  
  
  
3.19  CD14  stain  findings  
The  mean  CD14  positivity  was  highest  for  Osteoporosis  (2.71)  and  BRONJ  (2.59),  
and  lowest  for  OM  (0.56)  and  Healthy  (0.69).  This  was  statistically  significant  for  
Osteoporosis   (p  =   .044)  and  BRONJ   (p  =   .008)  when  compared   to   the  healthy  
group.  
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The  mean  CD68  macrophagic  cell  positivity  was  highest  for  Mixed  ONJ  (4.73)  and  
BRONJ  (4.30),  and  lowest  for  Healthy  (0.71).  This  was  statistically  significant  for  
Mixed  ONJ  (p  =  .001)  and  BRONJ  (p  <  .001)  when  compared  to  the  healthy  group  
as  well  as  to  the  osteoporosis  group.  
  
3.21  Micro-­CT  measurements  
Healthy  bone  demonstrated  the  highest  mean  percentage  of  medullary  space  to  
bone   (28.09%),   while   OM   (9.03%),   BPDN-­exposed   (9.63%),   BP-­exposed  
(10.40%),  ORN  (10.92%),  Mixed  ONJ  (12.30%),  BRONJ  (13.78%),  Osteoporosis  
(18.15%)  and  DRONJ  (19.69%)  all  demonstrated  a  significant  decrease  in  the  ratio  
of  medullary  space  to  bone  (Figure  26).    This  was  statistically    significant  for  OM  
(p  <   .001),  BPDN-­exposed  (p  =   .001),  BP-­exposed  (p  <   .001),  ORN  (p  <   .001),  
Mixed   ONJ   (p   <   .001),   BRONJ   (p   <   .001),   and   Osteoporosis   (p   =   .030).  
Osteonecrotic  disease  variants  exhibited  an  increased  mean  trabecular  width  with  
BPDN-­exposed  (654.36  µm),  Mixed  ONJ  (601.71  µm),  DRONJ  (504.75  µm),  BP-­
exposed   (476.96   µm),  ORN   (460.69),   and   BRONJ   (434.81   µm),   while   Healthy  
(259.07   µm)   exhibited   the   narrowest   trabecular   width.   This   was   statistically  
significant   for   Mixed   ONJ   (p   =   .033).   Of   the   bone   biopsies   from   patients   with  
BRONJ,  DRONJ,  and  Mixed  ONJ,  46  samples  were  labelled  as  border  bone,  26  
were   labelled  as  sequestrum  bone,  and  5  as  newly   formed  bone.  Analysis  was  
performed   both   including   and   excluding   sequestrum   bone   samples,   but   no  
significant   difference   was   observed.   The   presented   values   above   include  
sequestrum  bone  samples.  
  
	   68	  
  
Figure  26.  Micro-­computed  tomography  3D  reconstructions  of  bone  samples  
from  a  patient  with  osteoporosis  (left)  compared  to  a  patient  diagnosed  with  
denosumab-­related  osteonecrosis  of  the  jaw  exhibiting  thickened  plate-­like  
bone  trabeculae  (right).    
  
  
Part  III  Radiographic  evaluation  
  
3.22  Patient  population  
A   total   of   37  patients   (20   females  and  17  males)  age  44   to  92   years  old  were  
diagnosed  with   BRONJ   (n=28),   DRONJ   (n=6),   and  Mixed  ONJ   (n=3),   with   the  
majority  at  stage  2  (n=27)  and  stage  3  (n=9;;  Table  9).  A  total  of  22  patients  reported  
pain   upon   clinical   examination.   Patients   were   treated   with   antiresorptives   for  
primary   diagnoses   of   breast   cancer   (14/37),   prostate   cancer   (10/37),   multiple  
myeloma   (7/37),   osteoporosis   (3/37),   and   other   (3/37).   A   total   of   28   patients  
reported   concurrent   chemotherapies,   and   11   patients   were   taking   opioid  
medications  at  the  time  of  the  first  visit.  Five  patients  reported  a  smoking  history,  
while  32  were  non-­smokers.    
  
3.23  Clinical  characteristics  
The  onset  of  osteonecrosis  was  mostly  associated  with  dental  extractions  (n=20)  
or   pressure   sores   from   dental   prostheses   (n=16),   while   in   8   patients   another  
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association  was   reported   (i.e.,   implantitis,   periodontitis,   or   spontaneous   onset).  
Necrotic  sites  were   reported   in   the   right  mandible   (n=22),   left  mandible   (n=19),  
right  maxilla  (n=6),  and  left  maxilla  (n=4).  Most  patients  were  managed  operatively  
(29/37)   rather   than  non-­operatively   (8/37).  The  mean  duration  between   the   first  
visit  and  an  operation  was  136.7  ±  176.1  days  (range:  84  to  622  days).  Complete  
healing  (no  exposed  or  probeable  bone  with  no  complaint  of  pain)  was  observed  
in  19  patients,  and  non-­healing  was  reported  in  18  patients.  Patients  who  received  
operative   treatment   were   more   likely   to   be   healed   compared   to   patients   who  
received  non-­operative   treatment   (p  =   .001),  even  when  controlling   for  MRONJ  
stage,  pain,  and  number  of  non-­oral  and  oral  doses.  
  
3.24  Antiresorptive  dosing  
The  total  mean  number  of  non-­oral  doses  was  27  doses  (range:  1-­100  doses),  with  
26.3  ±  22.1  doses  (range:  1-­100  doses)  for  BRONJ,  10.8  ±  9.9  doses  (range:  1-­25  
doses)  for  DRONJ,  and  29.0  ±  26.2  doses  (range:  1-­51  doses)  for  Mixed  ONJ.  The  
mean  duration  of  oral  doses  was  7  months  (range  3-­84  months),  with  4.4  ±  16.5  
months   (range:  0-­84  months)   for  BRONJ  and  34.0  ±  48.0  months   (range:  0-­68  
months)   for  Mixed  ONJ.  The  majority  of  patients  were   treated  with  zoledronate  
(27/37)  and  denosumab  (8/37),  while  others  were  treated  with  alendronate  (3/37),  
risendronate  (2/37),  pamidronate  (2/37),  and   ibandronate  (2/37).  Antiresorptives  
were   administered   intravenously   (27/37),   orally   (5/37),   and   via   subcutaneous  
injection  for  denosumab  (8/37).  
  
3.25  Imaging  findings  
Necrotic  lesions  were  imaged  with  panoramic  radiograph  (n=134),  CBCT  (n=30),  
bone  scintigraphy  (n=18),  CT  (n=11),  and  MRI  (n=1).  We  excluded  MRI  from  the  
follow-­up  analysis  due  to  the  small  sample  size.  The  mean  duration  of  radiographic  
follow-­up  was   654.2   ±   417.6   days   (range:   163-­1990   days).   The  most   reported  
radiographic   signs   (Figure   27)  were   cancellous   bone   sclerosis   (34/37),   cortical  
bone   sclerosis   (32/37),   cortical   bone   erosion   (32/37;;   Figure   28),   persistent  
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extraction  sockets  (26/37;;  Figure  29),  sequestrum  (24/37;;  Figure  30),   thickened  
lamina   dura   (24/37),   bony   fistula   (17/37),   activity   on   bone   scintigraphy   studies  
(11/37),  inferior  alveolar  nerve  canal  changes  (10/37),  maxillary  sinus  involvement  
(7/37),  jaw  bone  fracture  (4/37),  and  cervical  lymph  node  involvement  (2/37).  There  
were  no  obvious  differences  in  radiographic  findings  with  regard  to  antiresorptive  
type,  MRONJ  disease  variant,  presence  of  pain,  and  healing.  More  radiographic  
findings  were  found  in  the  mandible  (p  =  .017).    
  
   Number  of  patients      Number  of  patients  
MRONJ  type      Primary  disease     
BRONJ     28   Breast  cancer     14  
DRONJ     6   Osteoporosis     3  
Mixed  ONJ     3   Prostate  cancer   10  
      Multiple  myeloma   7  
      Other  cancer   3  
Medications      Stage     
Zoledronate     27   1   1  
Alendronate     3   2   27  
Risendronate     2   3   9  
Pamidronate     2   Treatment     
Ibandronate     2   Operative   29  
Denosumab     8   Non-­operative   8  
Precipitating  
factor  
   Healing     
	   71	  
Extraction   20   Healed   19  
Dentures   16   Not  healed   18  
Other   8        
Pain      Smoking  
history  
  
Yes   22   Yes   5  
No   14   No   32  
Table  9.  Patient  characteristics  for  medication-­related  osteonecrosis  of  the  
jaw  disease  variants,  primary  disease,  antiresorptive  type,  staging,  
precipitating  factor,  presence  of  pain,  smoking  history,  treatment  type,  and  
healing  outcome.  MRONJ  =  medication-­related  osteonecrosis  of  the  jaw;;  
BRONJ  =  bisphosphonate-­related  osteonecrosis  of  the  jaw;;  DRONJ  =  
denosumab-­related  osteonecrosis  of  the  jaw.  
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Figure   27.   Most   common   imaging   findings   for   patients   diagnosed   with  
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Figure  28.  Cortical  bone  erosion  of  the  left  mandible  in  patients  treated  with  
zoledronate  (upper)  and  denosumab  (lower)  as  evidenced  by  panoramic  
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Figure  29.  Persistent  extraction  sockets  and  bony  fistula  demonstrated  on  
cone-­beam  computed  tomography  in  a  patient  with  bisphosphonate-­related  
necrosis  of  the  jaw  in  the  right  and  left  mandible  (left)  and  a  patient  with  
denosumab-­related  necrosis  of  the  jaw  in  the  left  and  right  maxilla  (right).    
  
  
 Persistent sockets and bony fistula 
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Figure  30.  Bone  sequestrum  in  the  right  mandible  of  a  patient  treated  with  
zoledronate  (upper)  and  in  the  left  mandible  of  a  patient  treated  with  
ibandronate,  zoledronate,  and  risendronate  (lower)  as  evidenced  by  
panoramic  radiograph  imaging.  
  
  
3.26  Comparison  of  imaging  modalities  
CBCT   was   better   for   visualizing   bony   fistula,   fracture,   and   the   extent   of   the  
sequestrum   (68.2%   detectability)   compared   to   CT   (30.8%   detectability).   CBCT  
detected   18.4%   more   findings   than   panoramic   radiograph   in   intraindividual  
comparisons   of   simultaneous   panoramic   radiograph   and  CBCT   studies   (Figure  
31).   CBCT  was   particularly   superior   for   denosumab   patients   with   poor   healing  
despite   minimal   radiographic   signs,   for   which   panoramic   radiograph   did   not  
Sequestrum 
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demonstrate   the  extent  of   the   lesion   (Figure  32).  CT  was  helpful   for  visualizing  
maxillary   sinus   involvement   and   cervical   lymph   node   involvement.   Panoramic  
radiograph  was  useful  for  visualizing  bone  sclerosis,  although  the  extent  was  not  
as  precise  as  3D  imaging  modalities.  
  
  
Figure  31.    Intraindividual  comparision  of  simultaneous  panoramic  film  
(left)  and  cone-­beam  computed  tomography  (right)  in  a  patient  with  mixed  
osteonecrosis  of  the  jaw  demonstrating  the  superiority  of  the  three-­
dimensional  imaging  modality  in  detailing  the  extent  of  cortical  bone  
erosion  in  the  right  mandible  from  the  lingual  to  buccal  plate.  
  
  
Panoramic film vs. CBCT 
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Figure  32.    Two  patients  with  denosumab-­related  osteonecrosis  of  the  jaw.  
Cone-­beam  computed  tomography  demonstrating  bony  fistula  in  necrotic  
sites  in  the  right  maxilla  (left).  Conventional  computed  tomography  of  a  
patient  with  maxillary  sinus  involvement  associated  with  a  site  of  
osteonecrosis  in  the  right  maxilla  (right).  
  
  
3.27  Radiographic  changes  over  time  
Patients  who  received  operative  treatment  were  more  likely  to  exhibit  improved  
or  stable  sequestrum  lesions  (p  =  .024),  even  when  controlling  for  age  (p  =  .011)  
and  presence  of  pain  (p  =  .014).  Patients  in  the  operative  group  were  also  more  
likely  to  have  improved  or  stable  bony  fistulas  compared  to  non-­operatively  
managed  patients  (p  =  .015),  even  when  controlling  for  age.  The  improvement  or  
worsening  of  other  radiographic  findings  such  as  persistent  extraction  socket,  
cortical  bone  erosion,  cortical  bone  sclerosis,  cancellous  bone  sclerosis,  
periosteal  sclerosis,  and  thickened  lamina  dura  did  not  exhibit  a  dependency  on  
having  had  operative  treatment.  An  attempt  was  made  to  describe  the  general  




 Bony fistula           Maxillary sinus 
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Although  the  first  incidence  of  MRONJ  was  described  over  fifteen  years  ago  with  
zoledronate[10],   the   pathogenesis   of   the   disease   continues   to   be   a   subject   of  
debate.  As  a  result,   there   is  no  consensus  on  a  unified   treatment  or  prevention  
paradigm.  Treatment  of  MRONJ  is  difficult  and  costly,  and  disease  sequela  can  
include  pain,  infection,  inability  to  eat,  extraoral  fistula,  and  pathologic  fracture,  all  
of  which  significantly  impact  the  quality  of  life  for  patients.[8,  9]  This  doctoral  project  
aimed   to   provide   a   more   profound   picture   of   how   BPs   and   denosumab   could  
influence   the  expression  patterns  of  HGFs  and  participating   cells   in  MRONJ   in  
vitro,   while   also   including   retrospective   histologic   and   radiographic   studies   to  
correlate  the  altered  bone  structure  with  different  disease  variants  and  degree  of  
antiresorptive  exposure.  
  
Our   research   found   that   fibroblast   cell   death   and   delayed   wound   healing   was  
observed  after  administration  of  antiresorptives,  in  particular  with  high  and  medium  
concentrations  of  nitrogen-­containing  BPs.  This  was  increased  by  the  introduction  
of  bacterial  LPS  and  a  co-­culture  with  a  THP-­1  mononuclear  cell  line.  There  was  
also  evidence  of  an  alteration  in  the  immune  response,  with  an  elevated  immune  
reaction  and  possible  dysfunction  as  a  result  of  antiresorptive  exposure.  In  both  
the   cellular   assays   with   gingival   fibroblasts   and   the   histologic   study,   we   noted  
some  effects  of  altered  osteoclast  activation  and   inhibition   through  RANKL  and  
OPG,  although  with  no  evidence  of  an  anti-­angiogenic  influence  (Figure  33).  Upon  
examination  of  the  bone  tissues  in  the  histologic  and  radiographic  study,  results  
suggested  that  a  limited  osteocyte  network  and  over-­ossification  of  the  bone  could  
play  in  a  role  in  MRONJ.  Many  of  these  findings  could  have  important  implications  
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Figure  33.  Key  research  findings  and  their   interconnections   in  the   in  vitro  
cellular  assays,  histologic  study,  and  radiographic  evaluation.  
  
  
4.1  Fibroblast  cell  death  and  delayed  wound  healing  
In  experiments  with  gingival  fibroblasts,  we  found  that  these  cells  of  the  soft  tissue  
were   susceptible   to   certain   antiresorptive   medications   at   high   and   medium  
concentrations.   Additional   concentrations  were   affected  with   the   introduction   of  
LPS   and   a   further   co-­culture   experiment   with   THP-­1   cells,   including   low  
concentrations   of   BP   and   combinations   of   zoledronate   and   denosumab,  
respectively.   Live/Dead   staining   results   confirmed   xCELLigence   adherence  
curves,  and  a  reduction  of  adherence  was  associated  with  HGF  cell  death  dose-­
dependently.  Scanning  electron  microscopy  also  further  displayed  the  drastically  
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altered   morphology   of   HGFs   and   the   deterioration   of   the   fibroblast   cell   layer  
exposed  to  antiresorptives.    
  
Although  MRONJ  is  primarily  considered  a  bone  lesion,  defective  or  delayed  oral  
mucosa  epithelialization   raises   the  question  of   the   role  of  soft   tissue   in  disease  
pathogenesis.[86]  As  BPs  are  renally  excreted  after  a  few  hours  in  circulation,  the  
medication   concentration   in   tissues   outside   bone   should   theoretically   be  
minimal.[87]  However,  apoptosis  and  decreased  proliferation  have  been  observed  
in  several  cell  types  including  cervical,  prostate,  and  intestinal  epithelial  cells  after  
exposure   to   BPs   in   vitro.[88-­90]   Reported   clinical   effects   include   chemical  
esophagitis  and  ulceration  occurring  in  patients  who  suck  on  BP  tablets.[91,  92]  
How  BPs  in  saliva  or  gingival  cervicular  fluid  may  have  apoptotic  effects  on  oral  
mucosa  remains  controversial.[69]  Some  authors  proposed  that  BPs  could  have  a  
direct  cytotoxic  effect  on  oral  mucosal  cells  due  to  a  leakage  of  the  drug  on  the  
overlying   mucosa,   with   greater   severity   when   administered   intravenously.[25]  
Irritation   of   the   oral   mucosa   could   easily   be   further   exacerbated   by   a   dental  
extraction  or  other  microtrauma.  To  this  effect,  if  high  concentrations  of  BPs  in  the  
oral   cavity  can  disrupt   the  mucosa,   it  may  be   reasonable   to  consider  how  high  
concentrations  in  the  underlying  bone  could  produce  a  similar  toxic  effect.[25]  A  
decreased  pH  due  to  infection  could  further  increase  the  acidic  environment  of  the  
osteoclastic   bone   resorption   sites,   increase   the   liberation   of   more   BPs   to   the  
surrounding  mucosa  and  bone.[93-­95]    
  
The  first  study  investigating  the  toxic  effects  of  the  soft  tissue  caused  by  BPs  was  
conducted   on   oral   keratinocytes.[41]   Several   research   groups   since   have  
confirmed   decreased   keratinocyte   proliferation   rates   and   viability,   increased  
apoptotic  changes,  and  decreased  migratory  capacity  in  keratinocytes  exposed  to  
BPs.[96,  97]  Pabst  et  al.   found   that  both  pamidronate  and  zoledronate   induced  
apoptosis  at  concentrations  of  50  µM  and  decreased  cellular  viability  of  gingival  
keratinocytes   at   5   µM.[96]   Histologic   samples   of   gingival   tissue   obtained   from  
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BRONJ  patients  demonstrated  swollen  and  hypereosinophilic  cells  with  a  picnotic  
nucleus   in   the  mucosal   layers  of   the  oral  cavity.[98]  Cytotoxic  effects  have  also  
been   reported   with   periodontal   ligament   fibroblasts   exposed   to   alendronate   in  
concentrations  higher  than  1  µM.[99]  Agis  et  al.  reported  decreased  cellular  activity  
in   periodontal   fibroblasts   which   underwent   apoptosis   in   vitro;;   however,   these  
adverse  effects  of  zoledronate  were  mitigated  by  the  presence  of  serum.[100]  
  
Gingival   fibroblasts   comprise   approximately   65%   of   the   total   cell   population   in  
healthy  gingival  connective  tissue.[101]  There  have  been  a  handful  of  studies  on  
HGF  cell  lines  or  primary  culture  cells  in  response  to  BPs.[40,  70,  95,  102,  103]  
Scheper  et  al.  reported  that  zoledronic  acid  released  from  the  bone  affects  gingival  
fibroblasts  as  well  as  oral  keratinocytes,  inducing  early  apoptosis  and  reducing  cell  
growth.[43]  Simon  et  al.  reported  toxicity  of  both  zoledronate  and  pamidronate  on  
gingival   fibroblasts.[104]   Another   study   demonstrated   that   alendronate,  
zoledronate,  and  pamidronate  decreased  collagen  production  and  cell  survival  in  
primary   HGFs.[44]   Significant   apoptosis   and   inhibited   cellular   proliferation   at  
concentrations   of   1,   5,   and   10   µM   of   zoledronate   on   HGFs   were   observed   to  
increase  with  concentration  and   time  up   to  7  days.[105]  Soydan  et  al.   reported  
cytotoxic   effects   of   both   parentally   administered   pamidronate   and   orally  
administered  alendronate,  which   induced  apoptosis  and   inhibited  proliferation   in  
primary  HGFs  in  vitro,  particularly  at  concentrations  ranging  from  10-­100  µM.[69]	    
  
We  observed  earlier  gingival  fibroblast  death  with  higher  concentrations  of  
nitrogen-­containing  BPs  (zoledronate,  alendronate,  and  ibandronate)  in  the  
xCELLigence  experiments,  with  cell  death  at  63-­78  hours  compared  to  controls  
of  90-­149  hours.  These  results  were  exacerbated  with  the  introduction  of  LPS  
and  a  co-­culture  of  THP-­1  cells,  which  affected  medium  and  low  concentrations  
of  nitrogen-­containing  BPs,  as  well.  Other  studies  also  confirmed  the  increased  
toxicity  of  aminobisphosphonates  on  a  variety  of  cell  types  including  endothelial  
cells,  fibroblasts,  and  osteogenic  cells  compared  to  non-­nitrogen-­containing  
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clodronate.[95]  Nitrogen-­containing  BPs  are  not  metabolized  and  therefore  
accumulate  in  the  bone[106],  whereas  non-­nitrogen  containing  BPs  such  as  
clodronate  are  rapidly  excreted  by  the  kidneys  with  far  less  uptake  by  cells.[107]  
BP  uptake  into  bone  is  in  direct  proportion  to  the  local  rate  of  bone  turnover,  and  
the  alveolar  ridges  of  the  maxilla  and  mandible  exhibit  a  high  turnover  rate.[108,  
109]    
  
Nitrogen-­containing  BPs  function  by  inhibiting  farnesyl  pyrophosphate  synthase,  
an  enzyme  in  the  mevalonate  pathway  (Figure  34).[70]  Lorenzo  et  al.  proposed  
that  the  mechanism  could  be  due  to  a  leakage  of  BP  from  the  jaw  bone,  
particularly  after  a  dental  extraction,  resulting  in  the  inhibition  of  the  farnesyl  
pyrophosphate  synthase  enzyme  in  surrounding  cells.[98]  There  has  been  
evidence  of  suppressed  epithelial  cell  growth  by  nitrogen-­containing  BPs  via  
inhibition  of  the  mevalonate  pathway  and  a  consequent  reduction  in  cholesterol  
synthesis.[110]  This  also  results  in  decreased  synthesis  of  the  metabolite  
geranylgeraniol,  interfering  with  cell  cycle  progression  and  blocking  
cytokinesis.[111]  Geranylgeraniol  is  necessary  for  membrane  localization  of  
intracellular  proteins,  including  caspase  3,  a  main  regulator  of  cellular  apoptosis,  
and  the  small  GTP-­binding  proteins  Ras,  Rho,  Rac,  and  Rap,  which  are  involved  
in  a  number  of  signaling  pathways.[69,  112]  Disturbance  of  these  important  
pathways  leads  to  an  inhibition  of  cell  migration,  cell  metabolism,  and  ultimately,  
apoptosis.  Alendronate  30  nM/ml  and  risedronate  10  nM/ml  were  found  to  inhibit  
human  epidermal  keratinocyte  proliferation  in  vitro  by  means  of  farnesyl  
pyrophosphate  synthase  inhibition.[110]  Suri  et  al.  reported  that  dose-­dependent  
apoptosis  and  loss  of  viability  in  intestinal  epithelial  cells  was  prevented  when  
BP-­induced  inhibition  of  farnesyl  pyrosphosphate  synthase  was  bypassed  with  
the  addition  of  the  downstream  product  geranylgeraniol.[113]  Other  researchers  
have  demonstrated  the  same  effect  with  gingival  fibroblasts,  where  proliferation,  
cellular  apoptosis,  and  migration  could  be  partially  rescued  by  geranylgeraniol  in  
vitro.[70,  71,  111]  
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Figure   34.   The   Mevalonate   Pathway.[111]   N-­BPs   =   nitrogen-­containing  
bisphosphonates;;  FOH  =  farnesol;;  GGOH  =  geranylgeraniol.  
  
  
We  also  observed  effects  on  wound  healing   in   the  24-­well  plate  scratch  assay.  
Impaired  wound  healing  was  observed  early  on  (after  72  to  96  hours)  in  nitrogen-­
containing   BPs,   a   non-­nitrogen   containing   BP,   as   well   as   a   combination   of  
zoledronate  and  denosumab  (specifically,  clodronate  500  µM,  ibandronate  5  µM  
and  50  µM,  alendronate  50  µM,  zoledronate  5  µM  +  denosumab  10  µg/mL,  and  
zoledronate  5  µM),  with  obvious  severe  fibroblast  cell  death  in  zoledronate  50  µM.  
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By   168   hours,   ibandronate   50   µM,   alendronate   50   µM,   zoledronate   5   µM   +  
denosumab  10  µg/mL  also  demonstrated  obvious  severe  cell  death  compared  to  
healthy-­appearing  confluent  controls.  When  comparing  our  in  vitro  observations  of  
increased   cell   death   and   delayed  wound   healing  which   intensified  with   time   to  
studies  in  patient  populations,  the  incidence  of  BRONJ  indeed  does  increase  with  
the  time  of  exposure,  from  1.5%  among  patients  treated  for  4–12  months  to  7.7%  
for  treatment  of  37–48  months.[114]    
  
Defective  or  delayed  epithelialization  of  the  oral  mucosa  has  also  been  observed  
in   almost   all   cases  of  BRONJ.[98]   If   the   local  medication   concentration   is   high  
enough,  it  inhibits  proliferation  of  adjacent  epithelial  cells[42]  and  slows  healing  of  
the   physical   breach   in   the   mucosa.[98]   Landesberg   et   al.   administered  
pamidronate   to   oral   keratinocytes   at   concentrations   of   3,   10,   30,   100   µM,   and  
reported   inhibited   cell   proliferation   and   impaired   wound   healing   at   the  
concentration  of  100  µM  with  no  evidence  of  cellular  apoptosis.  The  cell  layer  was  
closed  at  72  hours   for   the   lower  concentrations  of  pamidronate  and   the  control  
group.[41]  Pabst  et  al.  observed  cellular  apoptosis  of  oral  keratinocytes  as  well  as  
impairment   of   migration   in   a   scratch   assay   with   50   μM   of   nitrogen-­containing  
zoledronate,   ibandronate,   and   pamidronate   within   48   hours,   and   non-­nitrogen  
containing   clodronate   within   72   hours.[96]   Kobayshi   et   al.   conducted   a   wound  
healing   assay   which   demonstrated   that   zoledronate   1–10   µM   inhibited   the  
migration  of  murine  oral  keratinocytes  but  not  fibroblasts.[115]  
  
For  HGFs,  zoledonate,  pamidronate,  and  ibandronate  have  been  reported  to  affect  
healing   in   a   previous   wound   healing   scratch   assay.[95]   Previous   studies   have  
observed  that  zoledronate  impedes  proliferation  and  the  migratory  capacity/wound  
healing   of   gingival   fibroblasts,   suggesting   that   the   downregulation   of   type-­I  
collagen   transcription   could   be   a  mechanism,   as   it   is   necessary   to   deposit   the  
granulation  tissue  needed  for  re-­epithelization  in  keratinocyte  and  fibroblastic  cell  
lines.[103,   104]   Komatsu   et   al.   also   reported   a   reduction   of   type-­I   collagen  
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expression   via   transforming   growth   factor   beta   (TGF-­β)   suppression   in   HGFs  
exposed  to  zoledronate  at  serum  concentrations  of  1.47  μM.  They  proposed  that  
zoledronate-­induced  suppression  of  TGF‑β   resulted   in  decreased  HGF  viability  
and   migratory   activity   and   overall   impaired   fibrous   tissue   formation   by   HGFs  
possibly   through   the   inhibition   of   the   Smad‑dependent   signal   transduction  
pathway.[74]  A  theory  of  diminished  keratinocyte  growth  factor  (KGF)  production  
has   also   been   suggested   as   a   factor   in   the   mechanism   of   delayed   epithelial  
healing.  KGF   induces   growth   and  migration   of   gingival   epithelial   cells,   and   the  
combination  of  oral  bacteria  and  pamidronate  was  observed  to  promote  apoptosis  
of   gingival   fibroblasts,   a  major   source   of   KGF   production,   resulting   in   delayed  
epithelial  healing  combined  with  bone  death.[40]  
  
With   the  addition  of  LPS,   impediments   to  wound  healing  and  observed  gingival  
fibroblast  cell  death  occurred  earlier  and  were  affected  by  an  increased  number  of  
medications.  Zoledronate  50  µM  displayed  signs  of  cell  death  as  early  as  24  hours.  
By  48  hours,  wound  healing  was  affected  in  clodronate  500  µM,  denosumab  40  
µg/mL,  ibandronate  5  µM  and  50  µM,  zoledronate  0.5  µM  and  5  µM,  zoledronate  
5  µM  +  denosumab  10  µg/mL,  alendronate  50  µM,  with  zoledronate  50  µM  already  
having  already  progressed  to  severe  cell  death.  By  96  hours,  alendronate  50  µM  
also   exhibited   severe   cell   death.   A   murine   model   of   oral   bacteria   in   BRONJ  
exhibited   unhealed   gingival   epithelium   and   delayed   bone   regeneration   in  mice  
after  tooth  extraction  following  15  days  of  exposure  to  pamidronate  1mg/kg  and  
Fusobacterium  nucleatum   (F.   nucleatum).[40]   The   accompanying   in   vitro   study  
also  demonstrated  significantly  more  gingival  fibroblast  apoptosis  when  exposed  
to  the  combination  of  pamidronate  and  F.  nucleatum  compared  to  only  BP,  only  
bacteria,  or  control.  Zoledronate  1–10  µM  has  been  documented  to  promote  the  
adherence  of  Streptococcus  mutans  to  hydroxyapatite  and  the  proliferation  of  oral  
bacteria   obtained   from   healthy   individuals,   suggesting   that   zoledronate   may  
increase  bacterial  infection.[115]  Although  BRONJ  has  been  shown  to  develop  in  
rat  models  without  inflammation  or  oral  infection[33],    a  critical  role  of  oral  bacteria  
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in  the  pathogenesis  of  BRONJ  is  supported  by  clinical  studies  where  the  frequency  
of  necrosis   is  significantly  decreased  with   the  elimination  of  bacteria-­permeated  
dental  plaque  and  antibiotic  administration  prior  to  dental  surgery.[116-­118]  
  
Our   results   demonstrated   that   antiresorptives   were   toxic   to   HGF   even   without  
mechanical  damage.  In  the  non-­scratch  24-­well  plate  experiments,  zoledronate  50  
resulted  in  early  cell  death  at  24  hours,  while  ibandronate  50  µM,  zoledronate  50  
µM,  zoledronate  5  µM  +  denosumab  10  µg/mL,  and  alendronate  50  µM  progressed  
to  severe  cell  death  at  168  hours.  The  addition  of  LPS  worsened   the  effects  of  
alendronate   50   µM,   which   appeared   apoptotic   earlier   at   96   hours.   Due   to   the  
features  of   the  periodontal  anatomy   in  which   the  alveolar   ligament,  periosteum,  
gingival  mucosa,  and  the  dental  cervix  are  connected,  contact  between  BP  and  
the  soft  tissues  is  likely  to  occur  in  the  absence  of  traumatic  events  such  as  dental  
extraction.[98]  Scheper  et  al.  demonstrated  the  release  of  low  levels  of  zoledronate  
(0.25–3   µM)   from   bone,   which   may   induce   mucosal   cell   apoptosis   and   inhibit  
proliferation.[43]  Spontaneous  cases  occur  in  about  30%  of  patients[30],  which  are  
typically  localized  to  areas  that  are  easily  injured  with  thin  overlying  mucosa,  such  
as  in  the  mylohyoid  ridge  region.[41]  This  may  explain  the  onset  of  necrosis  due  
to  a  number  of  dental  prostheses  pressure  sores  in  both  our  histologic  (27%)  and  
radiographic  studies   (43%),  which  may  point   to  oral  mucosal  cell  death  without  
direct   trauma   to   the   oral   tissues.  One   clinical   study   reported   that   87%  of   adult  
patients   exhibited   traumatic   ulcerations   in   the   first   week   after   placement   of  
dentures,   followed  by  50%   in   the  second  week,  and  7%   in   the   third  week.[119]  
Niibe  et  al.  also  observed  a  statistically  significant  incidence  of  MRONJ  in  patients  
with  removable  dentures  compared  to  those  with  no  prosthesis.[120]  
  
Our  experiments  present  some  of  the  first  results  investigating  the  singular  effect  
of  denosumab  on  HGFs,  which  inhibited  wound  healing  at  high  concentrations  but  
otherwise  did  not  dismantle  the  fibroblast  cell   layer.  Oral  soft  tissue  toxicity  was  
previously  not  reported  with  denosumab.[7]  A  murine  model  has  demonstrated  that  
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denosumab  administration  resulted  in  a  significant   increase  in  CD3  and  gamma  
delta  (γδ)  T  cells  locally,  which  may  suggest  a  relationship  between  denosumab  
and   inflammation   with   delayed   connective   tissue   repair.[121]	   In   addition,  
monocytes   and   macrophages   have   been   reported   to   produce   isopentenyl  
pyrophosphate  (IPP)   in  response  to  BP  therapy,  which  also  activates  γδ  T  cells  
and   initiates   immune   responses   found   in  disease  states.[122,  123]   It   has  been  
noted  that  γδ  T  cells  cause  a  release  in  TNF  and  the  initiation  of  the  inflammatory  
acute  phase  response,  which  was  also  evidenced  by  elevated  TNF  expression  in  
our   in   vitro   assays.[124]   Denosumab   has   been   associated   clinically   with   non-­
specific  dermatologic  reactions,  which  could  be  attributed  to  the  suboptimal  tissue  
specificity   of   recombinant   molecules.[125,   126]   RANKL   and   RANK   are   also  
expressed   in   immune   cells   including   T   lymphocytes,   B   cells,   and   dendritic  
cells.[127,   128]   Since   RANKL   and   RANK   expressed   in   skin   cells   activates   T  
regulatory   cells   to   diminish   autoimmune   and   hypersensitivity   responses,   an  
inhibition   of   RANKL   may   disturb   normal   immune   activity.[126,   129]   In   our  
experiments  with  THP-­1  cells,  a  co-­culture  with   the  monocytic/macrophagic  cell  
line   resulted   in   significantly   earlier   HGF   cell   death   with   a   combination   of  
denosumab  and  zoledronate,  indicating  a  potential  immunologic  influence.  
  
These  results  are  one  of  the  first  to  address  the  effect  of  combined  concentrations  
of   zoledronate  and  denosumab,  which  attempted   to   simulate   the  actual   clinical  
situation  of  patients  who  have  received  BP  therapy  before  initiating  denosumab.[7]  
Since   the   half-­life   of  BPs   could   be   up   to   ten   years[103],   it  may   be   realistic   for  
patients  in  a  clinical  setting  to  have  residual  BP  effects  while  receiving  denosumab.  
In  order   to  untangle   the  distinct  differences   in  BP-­specific,  denosumab-­specific,  
and  combination  zoledronate  and  denosumab  effects,  we  included  three  different  
concentrations  of  BP  combined  with  denosumab.  In  particular,  the  concentrations  
of  zoledronate  5  µM  +  denosumab  10  µg/mL  demonstrated  severe  cell  death  with  
impaired  wound  healing,  which  was  also  seen  with  the  introduction  of  LPS.  This  
combination  also  resulted  in  HGF  death  without  mechanical  damage,  which  was  
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interestingly  not  observed  with  the  denosumab-­only  group.  This  implies  that  there  
may  be  an  influence  of  BP  on  HGFs  which  may  be  different  from  the  effect  exerted  
by  denosumab  alone.[130]  
  
  
4.2  Elevated  immune  response  and  possible  dysfunction  
Our   experiments   revealed   high   levels   of   IL-­8   and   TNF   gene   expression   with  
zoledonate  50  µM  in  the  presence  of  LPS  when  compared  to  control  groups  with  
and  without  LPS.  Denosumab  40  µg/mL  in  the  presence  of  LPS  also  demonstrated  
slightly  elevated  TNF  expression.  When  HGFs  were  cultured  with  THP-­1  cells,  IL-­
1β  was  elevated  with  all  concentrations  of  antiresorptive  except  for  control.   IL-­6  
levels  were  suppressed  significantly  in  high  concentrations  of  nitrogen-­containing  
BPs.  
  
Previous   research   in   the   field   of   periodontics   has   demonstrated   an   increased  
production   of   proinflammatory   cytokines   such   as   IL-­1,   IL-­6,   and   TNF   in   the  
periodontitis   disease   state   (Figure   35);;   these   cytokines   prime   neutrophils   and  
stimulate   bone   resorption.[131]  These   same   cytokines   are   also   elevated   in   the  
pathogenesis  of  oral  mucositis   following  cancer   therapy   leading  to  macrophagic  
tissue  destruction.[132]  IL-­8  is  produced  by  epithelial  cells,  and  is  responsible  for  
chemotaxis   and   angiogenesis   by   recruiting   neutrophil  migration   and   increasing  
monocyte   adhesion   in   the   blood   vessels.[66]   De   Colli   proposed   that   the  
overproduction  of   IL-­6,   IL-­1,  and  TNF-­α  are  closely   linked   to   the  occurrence  of  
inflammation   due   to   their   regulation   of   COX-­2   expression,   resulting   in   the  
production  of  key  inflammatory  mediators.[58]	  Periodontal  microbiota  such  as  P.  
gingivalis,   although   capable   of   direct   host   tissue   destruction,   are   also   able   to  
communicate  with  fibroblasts  and  epithelial  cells  to  stimulate  the  production  of  host  
mediators  and  cytokines.[133,  134]  The  synthesis  of   IL-­1α,   IL-­1β,  and  TNF-­α   in  
various   cell   lines   in   vitro   have   been   induced   by   LPS   from   Actinobacillus  
actinomycetemcomitans  
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(A.  actinomycetemcomitans)  and  P.  gingivalis.[135-­138]  These  cytokines  play  an  
important   role   in   inflammatory   osteoclastic   bone	   resorption   in   periodontal  
disease.[62,  139]    
  
P.  gingivalis  LPS   induces   IL-­1   release   from  macrophages[140]  and   IL-­1β      from  
fibroblasts  in  vitro[141]  as  well  as  in  vivo.[138]  Inflammation  caused  by  LPS  is  also  
mediated  at  least  in  part  by  IL-­1β.  The  LPS  from  P.  gingivalis  is  a  potent  stimulator  
of   bone   resorption   in   vitro.[139]   IL-­1β   has   also   been   demonstrated   to   play   an  
important  role  in  osteoclastic  bone  resorption  in  vitro  [142,  143]  and  in  vivo.[62-­64]  
  
As   a   part   of   the   innate   immunity   response,   TNF-­α   plays   a   central   role   in   the  
inflammatory  reaction,  alveolar  bone  resorption,  and  the  loss  of  connective  tissue  
attachment  in  periodontal  disease.[144]  TNF-­α  is  locally  produced  by  a  number  of  
cell   types,   including   neutrophils,   which   exhibit   increased   chemotaxis   and  
production   of   proinflammatory   cytokines.[131]   Macrophages   represent   an  
important   source   of   TNF-­α,   that,   under   dysregulation,   contribute   to   host   tissue  
destruction.[145]	   The   loss   of   fibroblasts   that   occurs   during   infection   with  
periodontal  pathogens  is  also  mediated  by  TNF.[61]  Graves  et  al.   indicated  that  
the  destruction  of  the  periodontium  may  very  well  represent  an  overreaction  of  the  
host  response  to  periodontal  pathogens  caused  by  excessive  production  of  IL-­1  
and   TNF.[61]   In   murine   models,   BRONJ   was   seen   to   be   associated   not   with  
infection  but  instead  with  severe  inflammation  and  immunosuppression[33,  146];;  
therefore,  immune  dysregulation  could  be  a  factor  in  BRONJ  pathogenesis.  
  
Other   authors   have   suggested   a  mechanism   of   reduced   host   defense   against  
infection   induced  by  antiresorptive  medications.[16]   In  previous  experiments  we  
demonstrated   that   BPs   suppressed   macrophage   differentiation,   migration,   and  
phagocytosis   in   vitro.[34,   36]   Partial   inhibition   of   early   T   and   B   lymphocyte  
development   has   been   observed   in   RANKL-­deficient   mice.[52]	   It   is   also  
conceivable   that   recombinant  denosumab  molecules  not  completely  specific   for  
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RANKL  could  react  with  other  receptors  in  the  TNF  family  to  produce  disruptions  
in   the   immune   system.[126]   In   our   experiments   with   HGFs,   we   noted   that  
denosumab  in  combination  with  LPS  did  indeed  increase  the  levels  of  TNF,  as  well  
as  IL-­1β.  Clinically,  severe  infections  requiring  hospitalization  including  cases  of  
diverticulitis,   cellulitis,   and   erysipelas   have   been   reported   with   denosumab  
treatment.[147,  148]  One  could  hypothesize  that  denosumab  could  play  a  role  in  
exacerbating   chronic   infection,   which   may   be   relevant   in   the   field   of   clinical  
periodontics,  although  there  is  no  literature  addressing  this  to  date.    
  
  
Figure  35.  Network  of  cytokines  involved  in  periodontal  disease.[145]  
  
  
Increases   of   IL-­1β,   TNF,   and   IL-­8   in   HGFs   exposed   to   antiresorptives   in   our  
experiments  suggest  a  pro-­inflammatory  environment  as  seen  in  other  diseases  of  
the  oral  cavity  such  as  periodontitis  and  mucositis.  However,  we  found  that  levels  
of  IL-­6  were  elevated  for  every  concentration  including  the  control  except  for  the  
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highest   concentrations   of   zoledronate,   alendronate,   and   ibandronate.   Since    
zoledronate  50  µM,  alendronate  50  µM,  ibandronate  50  µM  were  the  most  toxic  
concentrations   for  HGF  viability,   the   lack  of  expression   in   these  concentrations  
was  a  point  of  interest.  IL-­6  is  an  important  regulator  of  the  immune  system;;  IL-­6  
levels   are   normally   present   in   healthy   patients   and   are   then   increased   in   a  
periodontal  disease  state.[149]  IL-­6  plays  a  major  role  in  B  cell  differentiation  in  the  
adaptive  immune  response.[65]  B  cells  are  activated  and  transformed  into  plasma  
cells,  which  produce  antibodies  against  bacterial  antigens.  Since  IL-­6  is  necessary  
for  this  switch  to  a  more  sophisticated  immune  response,  an  absence  or  decrease  
of   IL-­6   in   high   concentrations   of   aminobisphosphonates   could   suggest   a  
dysfunction  in  the  later  stages  of  the  immune  response.  It  could  be  possible  that  
HGFs  exposed  to  antiresorptives  and  bacterial  challenge  remain  in  the  initial  pro-­
inflammatory  stage,  unable  to  activate  the  acquired  immune  system  and  resolve  
inflammation.  However,  other  research  groups  have  also  reported  increased  IL-­6  
levels  expressed  by  HGFs  exposed  to  BPs.[58,  101]  
  
Saracino  et  al.  suggested  that  a  switch  to  a  pro-­inflammatory  microenvironment  
could   play   in   a   role   in   pathogenesis   after   observing   an   increase   of   TNF-­α   in  
keratinocytes  exposed  to  zoledronate  5  µM  and  50  μM.[42]	  Our  results  also  seem  
to   support   the   theory   that   antiresorptives   in   combination   with   infection/LPS  
promote  an  immunologic  reaction  in  HGF  cells,  which  could  be  indicative  of  some  
type   of   ineffective   immunologic   overstimulation   leading   to   local   immune  
dysfunction.[35,  36]  The  results  of  our  histologic  study  seemed  to  corroborate  with  
this  idea.  We  did  see  more  signs  of    infectious  infiltration  in  BRONJ,  DRONJ,  and  
Mixed   ONJ   compared   to   healthy   and   osteoporosis   samples,   as   well   as   a  
significantly  higher  Allred  Score  with  CD14  and  CD68  for  BRONJ  and  Mixed  ONJ  
bone  specimens  compared  to  healthy  control  groups.  There  was  also  evidence  of  
macrophage  differentiation  of  THP-­1  cells  exposed  to  antiresorptives  and  LPS  in  
co-­culture  with  fibroblasts,  along  with  release  of  the  aforementioned  cytokines.    
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CD14  is  a  glycoprotein  released  by  monocytes  and  macrophages  localized  on  cell  
membranes,  and  is  mainly  expressed  by  macrophagic  cells  and  to  a  lesser  extent  
by   neutrophil   granulocytes.[35]   CD14-­positive   monocytes   can   differentiate   into  
various   cells   and   interact   with   and   bind   to   LPS,   a   potent   activator   of  
macrophages.[150]   CD14   plays   in   a   role   in   activating   a   signalling   pathway   for  
optimal  inflammatory  gene  expression  induced  by  LPS  from  Escherichia  coli  or  P.  
gingivalis  through  toll-­like  receptors  in  macrophages.[150]  
  
CD68  is  also  expressed  by  macrophages/monocytes,  and  is  particularly  useful  as  
a  marker   for   the  various  cells  of   the  macrophage   lineage,   including  monocytes,  
histiocytes,  giant  cells,  Kupffer  cells,  and  osteoclasts.[151,  152]  Expression  levels  
of  CD68  are  also  connected  to  the  phagocytic  activity  of  macrophages.[35]  Hoefert  
et  al.  observed  an  decreased  CD68   infiltration  and  CD68/CD14  ratio   in  BRONJ  
specimens   compared   to   jaw  bone   specimens   of   patients  with  OM  or  ORN.[35]  
Other   groups   have   reported   an   increased  macrophage   cell   density   in   BRONJ-­
affected   jaw  bone  compared   to  ORN  and  control   groups[153],   and  comparable  
results  in  murine  models  for  CD68  positivity  in  rats  treated  with  BPs.[154]  
  
Macrophages,   like  osteoclasts,   can   internalize  and  be  affected  by  BPs.[155]   In  
addition   to   their   role   in   initiating   the   immune   response   against   pathogens,  
macrophages  are  also   crucial   to   tissue  homeostasis  and   regeneration.[156]  An  
excessive   response   of   the   macrophage   lineage   may   indicate   some  
disproportionate   reaction   from   the   innate   immune   system.   The   increased  
macrophagic  infiltration  in  BRONJ  specimens  could  be  stimulated  by  local  infection  
but  also  by  the  action  of  BPs.[153]	  Wehrhan  et  al.  found  an  increased  macrophage  
cell  density  in  BRONJ-­affected  jaw  bone,  and  proposed  that  it  could  be  due  to  a  
BP-­caused  shift  from  the  M2  to  a  M1  macrophage  cell  type.[153]  M2  macrophages  
are  associated  with  tissue  homeostasis  and  regeneration,  while  M1  macrophages  
cause   tissue   destructive   inflammation.[157,   158]   M1   phenotype   activation   has  
been   also   associated   with   an   increase   in   TNF-­α   and   IL-­1β,   which   was   also  
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confirmed   in   our   in   vitro   assays.[159]   Additionally,   recent   groups   have   also  
reported   that   IL-­6   is   important   for   the   switch   in   macrophage   polarization.[153]  
Thus,  a  BP-­derived  shift  towards  M1  polarization  might  prevent  a  M2  macrophage-­
mediated  wound  healing  response  in  BRONJ  affected  sites[35,  160],  resulting  in  a  
continued  inflammatory  process  which  is  unable  to  resolve.  This  failure  to  switch  
from  an  inflammatory  M1  type  to  a  regenerative  M2  type  has  also  been  observed  
in  unhealed  chronic  venous  ulcers.[161]  
  
The   immunomodulatory   capacity  of  BPs  has  been  proposed  due   to  direct   anti-­
tumor  effects  in  patients  treated  with  BPs  for  malignant  diseases  in  the  absense  of  
bone   involvement.[162,   163]   There   is   evidence   that   BP   treatment   decreases  
RANKL  expression  and  consequently  reduces  nuclear  factor  kappa-­B  activation,  
a  gene  regulator  implicated  in  many  cancers  which  also  has  a  role  in  increasing  
macrophage  polarization  to  the  M2  phenotype.[164-­167]  A  shift  from  M2-­polarized  
macrophages   to   M1   might   explain   the   clinically   observed   anti-­tumor/tissue  
destructive  effects  of  BPs  even  in  the  absence  of  bone  metastases[168],  as  well  
as  the  predominance  of  the  tissue-­destructive  phenotype  potentially  leading  to  the  
development  of  BRONJ.[153]	  This   theory  was   further   supported  by   the  work  of  
Zhang   et   al.,   who   noted   that   the   adoptive   transfer   of   M2   macrophages   could  
reduce  BRONJ  severity  in  mice.[160]  Zoledronate  but  not  denosumab  has  been  
demonstrated   to   suppressed   THP-­1   macrophagic   differentiation   and   cell  
function.[34]  Our  results  likewise  lead  us  to  propose  that  denosumab  could  have  
a   different   mechanism   of   action   than   BPs   in   causing   tissue   destruction.  
Macrophage  involvement  and  absent  IL-­6  levels  were  observed  in  our  in  vitro  and  
histologic  studies  involving  BRONJ  but  not  DRONJ,  which  we  hypothesize  to  be  
more   associated   with   disturbed   T   and   B   cell   immunity,   local   inflammation,  
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4.3  Osteoclast  activation  and  inhibition  
In  our  experiments  with  connective  tissue  cells,  we  observed  that  the  expression  
of  RANKL  by  HGFs  was  not  significantly  influenced  by  antiresorptives.  However,  
high  doses  of  zoledronate  50  µM  with  LPS  (and  slightly  denosumab  40  µg/mL)  
with  LPS  elevated  the  expression  of  OPG  compared  to  controls  with  and  without  
LPS.  RANKL  is  a  member  of  the  TNF  cytokine  family  and  is  secreted  by  fibroblasts,  
as  well  as  osteoblasts  and  other  stromal  cells,  to  promote  osteoclast  activation  and  
differentiation.[169,   170]   OPG   is   a   cytokine   receptor   also   from   the   TNF   family  
which   functions   as   a   decoy   receptor   for   RANKL,   inhibiting   the   RANK-­RANKL  
interaction   and   thus   osteoclastogenesis   by   tightly   binding   to   RANKL.[171]  
Fibroblasts,  as  well  as  osteoblasts  and  cells  of  the  immune  system,  can  produce  
both  OPG  and  RANKL.  LPS  has  also  been  demonstrated  to  have  a  direct  effect  
on  fibroblasts,  causing  them  to  increase  the  expression  of  RANKL  and  IL-­6.[172]  
Since  RANKL  levels  were  low  and  levels  of  OPG  were  higher  in  our  experiments  
of   fibroblasts   exposed   to   both   zoledronate   and   denosumab,   our   results   could  
indicate  that  fibroblast  signaling  in  osteoclastic  bone  remodelling  is  suppressed  in  
the   presence   of   a   combination   of   infection/LPS   and   antiresorptive,   but   not  
antiresorptive   alone.   Therefore   it   seems   a   bacterial   challenge   is   needed   to  
increase  the  expression  of  OPG,  thereby  inhibiting  RANKL  and  bone  resorption.  
  
Previous  studies  have  confirmed  our  results  with  HGFs,  where  OPG  was  detected  
at   high   levels   in   gingival   fibroblast   cultures,   and   RANKL   could   not   be  
detected.[173]   Tipton   et   al.   also   found   that  OPG   levels   increased   and  RANKL  
levels   decreased  when  HGFs  were   exposed   to   alendronate   or   pamidronate   at  
concentrations   of   0.01   nM   to   1   µM,   and   these   effects   were   amplified   when  
stimulated   by   LPS.[101]  Human  periodontal   ligament   cells   stimulated  with   LPS  
inhibited  osteoclastogenesis   by  producing  more  OPG   than  RANKL   through   the  
induction   of   IL-­1β   and   TNF-­α.[174]   This   correlated   with   our   observations   of  
increased  OPG,  IL-­1β,  and  TNF  cytokine  expression  with  decreased  RANKL  gene  
expression.    
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Our  histologic  study  of  bone  specimens  revealed  that  RANKL  staining  was  most  
positive  for  BRONJ  (p  =  .021  compared  to  Healthy)  and  Mixed  ONJ,  and  least  
positive  for  Healthy  and  DRONJ.  The  results  for  TRAP  stain  corroborated  with  
this  as  Mixed  ONJ  (p  =  .002),  BRONJ  (p  <  .001),  and  BP-­exposed  (p  =  .017)  
exhibited  a  higher  Allred  Score  compared  to  the  healthy  group.  The  number  of  
osteoclasts  counted  were  also  highest  for  Mixed  ONJ  (p  =  .041),  BRONJ  (p  =  
.034),  and  lowest  for  Healthy.  In  contrast,  OPG  positivity  was  highest  for  DRONJ  
and  Mixed  ONJ  and  lowest  for  Healthy,  although  the  results  were  not  of  statistical  
significance.  It  is  of  interest  to  find  an  increased  number  of  osteoclasts  in  
BRONJ-­affected  bone,  since  the  accepted  mechanism  of  action  of  BPs  is  to  
prevent  osteoclast  function.[175]  Most  research  groups  have  reported  a  
decrease  or  absence  of  multinucleated  osteoclasts  and  no  signs  of  bone  
remodeling  in  necrotic  BRONJ  sites[176,  177],  although  a  statistically  significant  
higher  number  of  osteoclasts  in  tissue  samples  of  patients  with  BRONJ  has  been  
previously  reported.[178,  179]    
  
Baron  et  al.  suggested  that  BP-­induced  osteoclast  inhibition  could  trigger  a  
feedback  loop  resulting  in  the  increase  of  RANKL  and  subsequent  osteoclast  
differentiation.[5]  Hansen  et  al.  propose  that  this  increase  in  osteoclasts  is  
probably  not  only  related  to  resorption  of  sequestrated  bone[180],  but  also  the  
dysfunctional  degradation  of  vital  and  functional  jaw  bone.[178]  Of  the  20%  to  
80%  of  absorbed  BP  taken  up  by  bone,  a  high  percentage  has  been  reported  at  
sites  of  bone  formation  and  even  higher  for  sites  of  bone  resorption.[95]  In  our  
study,  we  also  noticed  that  Mixed  ONJ  and  BRONJ  exhibited  more  areas  of  
scallopped  resorption  in  both  necrotic  and  vital  bone,  with  multinucleated  
osteoclastic  cells  in  Howship  lacunae  participating  in  bone  destruction  and  
resorption.	  These  areas  of  osteonecrosis  also  appeared  to  be  patchier  in  tissue  
specimens  of  BP-­treated  patients  when  compared  with  larger  regions  of  necrotic  
bone  in  ORN.[179]	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Higher  numbers  of  osteoclasts  could  be  also  explained  by  a  stimulating  presence  
of  bacteria  in  the  oral  cavity.  An  association  between  infection  with  Actinomyces  
and  osteolysis  has  been  long  established.[181]  The  increased  recruitment  of  
osteoclasts  in  Actinomyces-­positive  osteonecrosis  as  reported  in  a  previous  
study  argues  for  a  stimulatory  effect  of  a  microbial  presence.[178]  Some  bacteria  
have  been  demonstrated  to  directly  regulate  the  production  of  RANKL  in  human  
periodontal  ligament  cells,  gingival  fibroblasts,  B  cells,  and  macrophages,  
resulting  in  increased  bone  resorption.[16,  182]  A.  actinomycetemcomitans  and  
P.  gingivalis,  both  common  pathogens  in  periodontitis,  have  been  shown  to  
cause  a  similar  increase  in  bone  erosion  in  animal  models  and  have  been  cited  
as  possible  agents  in  BRONJ  development.[138,  183]	  These  gram-­negative  
anaerobic  bacteria  contain  a  complex  inflammatory  LPS  in  their  cell  walls  which  
can  independently  participate  in  host  cell  cytokine  synthesis  and  bone  resorption.  
Proteins  from  P.  gingivalis  have  been  reported  to  directly  regulate  RANKL  and  
OPG  production  in  human  periodontal  ligament  fibroblasts  and  HGFs,  increasing  
osteoclastogenesis.[184]  This  may  explain  MRONJ  cases  exhibiting  extensive  
sequestration  despite  antiresorptive-­suppressed  bone  turnover.  Osteoclasts  
stimulated  by  bacteria  could  additionally  activate  inflammatory  cells  and  induce  
the  synthesis  and  release  of  cytokines  such  as  TNF,  IL-­1,  and  IL-­6,  as  observed  
in  periodontitis.[185]  Reports  of  scallopped  bone  on  surfaces  affected  by  
BRONJ[179,  186,  187]  has  also  been  attributed  to  bacteria,  cytokines,  and  
associated  fibroblast-­like  cells  which  have  the  ability  to  directly  resorb  bone  
independent  of  osteoclasts  via  the  release  of  various  acids  and  proteases.[28,  
188-­191]  This  suggests  that  the  theory  of  osteoclast  inhibition  alone  does  not  
explain  the  elective  localization  of  the  disease  in  maxillofacial  area,  and  that  
other  mechanisms  must  play  a  role  in  the  pathogenesis  of  BRONJ.[98]  
  
Hansen  et  al.  proposed  that  pseudoepitheliomatous  hyperplasia  could  play  a  role  
in  allowing  bacteria  to  reach  the  bone,  since  they  observed  the  presence  of  
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bacteria  situated  between  the  bone  and  altered  epithelium  in  several  cases  of  
BRONJ.[179]  While  pseudoepitheliomatous  hyperplasia  normally  occurs  as  a  
rare  complication  of  chronic  osteomyelitis  of  long  bones  such  as  the  tibia,  it  
occurs  seldomly  in  the  jaw.[192]  Typically,  this  lesion  is  distinguished  by  
nonkeratinized  squamous  epithelium  without  signs  of  atypia  exhibiting  a  distinct  
centrifugal  involvement  of  medullary  spaces.[179]  In  our  histologic  study,  we  
observed  that  BP-­exposed  bone  exhibited  more  pseudoepithelial  changes.  Zustin  
et  al.  observed  the  appearance  of  pseudoepitheliomatous  hyperplasia  in  the  
bone  specimens  of  11  out  of  17  BRONJ  patients  and  suggested  that  it  could  be  a  
response  of  the  oral  tissues  to  re-­epithelialize  and  create  a  physical  barrier  from  
inflamed  regions.[193]  We  also  observed  pseudoepitheliomatous  hyperplasia  in  
BRONJ  and  Mixed  ONJ,  with  the  presence  of  granulation  tissue  in  non-­necrotic  
bone  samples,  which  has  associated  in  the  literature  with  bacterial  debris  in  
Mixed  ONJ  and  BRONJ.[194,  195]    
  
In  our  study,  pseudoepitheliomatous  hyperplasia  occurred  more  frequently  in  
cases  associated  with  BPs  than  denosumab,  particularly  in  non-­necrotic  bone  
still  able  to  respond  to  injury  via  epithelial  changes.  Hokugo  et  al.  proposed  that  
this  reaction  could  be  due  to  an  upregulation  of  TNF-­α  and  interferon  gamma  
(IFN-­γ)  induced  by  increased  T  helper  cytokines.[37]  In  our  laboratory  studies,  
we  also  noted  a  greater  increase  of  TNF  levels  in  gingival  fibroblasts  upon  
administration  of  zoledronate  compared  to  denosumab.  Furthermore,  we  
observed  that  fibrous  tissue  was  more  frequently  found  in  the  osteoporosis,  
osteomyelitis,  and  BPDN-­exposed  groups  with  a  more  organized  appearance  in  
osteoporosis  samples.  Favia  et  al.  reported  collagen  deposition  in  non-­necrotic  
bone  from  ONJ  patients.[39]  Interestingly,  fibrotic  diseases  are  believed  to  be  
associated  with  the  M2  polarization  of  macrophages,  which  is  much  less  tissue-­
destructive  than  the  M1  profile.[196]  
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Besides  bacterial  stimulation  of  osteoclasts,  an  increased  positivity  of  osteoclastic  
staining  in  our  study  could  also  be  explained  by  the  presence  of  osteoclasts  that  
survive   but   are   non-­functional.   Previous   results   have   shown   that   zoledronate  
inhibits  bone  healing  by  suppressing  osteoclast  activation  despite  positive  TRAP  
staining.[106]  Lim  et  al.  observed  that  with  a  concentration  of  1  µM  zoledronate  in  
rats,  cells  were  stained  with  TRAP  but  failed  to  fuse  and  form  active  osteoclasts.  
Osteoclasts  detected  in  inflammatory  areas  from  treated  patients  were  small  and  
contained   few   nuclei.[39]   It   was   discovered   that   osteoclasts,   which   arise   from  
macrophagic  precursors,  normally  also  express  a  M2-­like  cytokine  profile,  but  are  
induced  by  nitrogen-­containing  BPs  to  a  shift  towards  an  M1-­like  pro-­inflammatory  
profile.[197]   Since   osteoclasts   are   formed   by   the   fusion   of   mononuclear   cells,  
some   authors   propose   that   a   shift   from   a  M2   to   a  M1  macrophage   progenitor  
microenvironment  in  BRONJ-­affected  bone  could  additionally  block  the  the  fusion  
of   hematopoietic   precursors   into   multinucleated,   mature   osteoclasts.[153,   198]  
Since   BPs   could   also   inhibit   bone   resorption   by   preventing   mature   osteoclast  
formation,  this  may  result  in  an  accumulation  of  functionally  inactive  osteoclasts.[5,  
198]  In  organ  culture,  some  BPs  have  been  observed  to  inhibit  the  generation  of  
mature   osteoclasts,   possibly   by   preventing   the   fusion   of   osteoclast  
precursors.[199]  Williams  et  al.  proposed  that  these  impaired  osteoclasts  are  then  
unable   to   remove   bacteria-­infested   bone   in   MRONJ   lesions,   leading   to   bone  
death.[200]    
  
Since  osteoclasts   and  macrophages  derive   from  a   common  precursor,   another  
hypothesis  is  that  positive  RANKL  or  TRAP  stains  for  osteoclast-­like  cells  could,  in  
fact,  actually  be  macrophages  with  osteoclast-­like   functions,  as  no  truly  specific  
osteoclast  markers  are  available.  Positive  TRAP  staining  has  been  reported   for  
osteoclast   precursors   before   fusion   and  activation.[201]  Since   intermediate   cell  
types  in  the  continuum  between  macrophages  and  osteoclasts  do  exist,  including  
mononuclear  osteoclasts  and  polynuclear  macrophages[198],  there  could  be  a  cell  
type  that,  when  converted  by  certain  cytokines,  begins  to  dysfunctionally  resorb  
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the  bone.  This  could  perhaps  occur  despite  or  even  due  to  antiresorptive  inhibition  
of  mature   osteoclasts   and  expressed  with   positive  TRAP  and  RANKL   staining.  
Macrophages,   osteoclast-­like   cells,   and   fibroblast-­like   cells   have   all   been  
demonstrated   to  participate   in  osteoclast-­independent  bone   resorption.[28,  189,  
202]  There  has  been  evidence  of  mononuclear  macrophage-­like  cells  at  sites  of  
cartilage  resorption  which  expressed  a  TRAP-­positive  osteoclast  phenotype.[203]  
Immune   modulators   and   hormones   have   been   observed   to   induce   mature  
macrophages  to  differentiate  into  osteoclasts  in  vitro.[204]  Our  previous  study  with  
THP-­1  cells  also   revealed   that   zoledronate  affected  macrophagic  differentiation  
and  function.[34]  However,  macrophagic  activity  was  not  affected  by  denosumab.  
This  concurred  with  the  results  from  our  histologic  study,  where  DRONJ  samples  
did  not  demonstrate  evidence  of  macrophagic-­osteoclastic  involvement,  nor  cells  
positive  for  RANKL  and  TRAP  staining  like  the  BRONJ  group.  This  may  be  due  to  
the  explicit  effects  of  denosumab  on  RANKL  inhibition  and  supports  the  idea  of  a  
different   mechanism   of   action   between   DRONJ   and   BRONJ.   The   influence   of  
exclusive   denosumab   effects   may   have   been   previously   confounded   due   to  
DRONJ  patients  who  were  often  initially  exposed  to  other  antiresorptives  in  prior  
studies.  However,  in  our  study,  the  DRONJ  group  represented  a  cohort  of  patients  
without  a  history  of  other  prior  antiresorptives.  Of  interest  is  the  variable  results  for  
Mixed  ONJ,  which  may  depend  on  whether  the  necrotic  lesion  is  influenced  more  
predominantly  by  BP  or  denosumab  effects.    
  
  
4.4  No  evidence  of  affected  angiogenesis  
We   did   not   find   any   evidence   of   decreased   angiogenesis   in   any   of   our  
investigations.   Results   from   ELISA   quantifications   of   VEGF   revealed   that   all  
concentrations   with   and   without   antiresorptive   medications   were   elevated,  
indicating  no  signs  of  anti-­angiogenic  effects  on  HGFs  exposed  to  antiresorptives.  
We  also  observed  IL-­8  gene  expression  with  zoledronate  50  µM  in  the  presence  
of  LPS.  Since  IL-­8  is  also  responsible  for  monocyte  adhesion  in  the  blood  vessels,  
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it  can  also  serve  as  a  marker  for  affected  angiogenesis.[66]  In  the  histology  study,  
the   blood   supply   by   Haversian   systems   showed   no   significant   observable  
differences;;  interestingly,  there  was  even  a  slight  tendency  for  a  higher  Haversian  
canal  density  in  bone  affected  by  DRONJ,  BRONJ  and  Mixed  ONJ  with  observable  
intact  vasculature.    
  
Anti-­angiogenic   properties   of   antiresorptives   have   long   been   indicated   as   a  
mechanism   for   MRONJ   development.[31,   88,   205,   206]   A   reduction   of   blood  
vessels   in   ONJ   patients[207]   as   well   as   inhibition   of   vascular   endothelial   cell  
proliferation  and  migration  has  been  reported.[208]  Others  hypothesize  that  anti-­
angiogenic   effects   could   be   attributed   to   incorrect   processing   of   vascular  
endothelial  growth  factor  receptor  2  (VEGFR2)  on  endothelial  cells  resulting  in  an  
intracellular  accumulation  induced  by  zoledronate.[209]  Yamashita  et  al.  found  that  
while  VEGF-­A  was  not  affected  by  zoledronate,  VEGF-­C,  which  is  responsible  for  
lymphangiogenesis,  was  suppressed  in  rats.[210]  
  
We  did  not  observe  any  evidence  for  anti-­angiogenic  effects  in  our  experiments.  
Other  in  vivo  studies  have  also  failed  to  demonstrate  a  strong  relationship  between  
BP  treatment  and  reduced  angiogenesis.[211,  212]  In  fact,  several  groups  have  
even   reported   an   upregulation   of   VEGF-­A   and   bone   morphogenetic   protein   2  
(BMP-­2)  gene  expression,  suggesting  that  fibroblasts  respond  to  zoledronic  acid  
by  producing  a  pro-­angiogenic  environment.[111,  213]  Tseng  et  al.  reported  that  
IL-­8  levels  were  significantly  upregulated  in  osteoclasts  treated  with  zoledronate.  
Both  human  bone  specimens  and  a  canine  model  of  BRONJ  exhibited  a  visible  
and   intact   vasculature   despite   being   surrounded   by   areas   of   nonviable  
osteocytes.[179,  214]  An  increased  or  continued  vascular  flow  to  affected  regions  




	   101	  
4.5  Limited  osteocyte  network  and  over-­ossification  
The  results  of  our  histologic  study  demonstrated  significantly  fewer  total  numbers  
of  osteocytes  per  µm2    in  DRONJ  (p  =  .007),  BP-­exposed  (p  =  .028),  BPDN-­
exposed  (p  =  .022),  and  ORN  (p  =  .004)  compared  to  Osteoporosis.  DRONJ  
lesions  exhibited  a  decreased  amount  of  osteocytes  initially  when  compared  to  
the  healthy  group,  and  this  distinction  became  even  more  clear  when  compared  
to  the  osteoporosis  group  since  both  cancer  patients  (breast  and  prostate)  and  
osteoporosis  patients  frequently  begin  antiresorptive  therapy  in  an  osteopenic  
state.  A  decreased  osteocyte  density  was  also  reported  by  other  groups  in  both  
patients  treated  with  alendronate  compared  to  osteoporosis  and  those  with  active  
BRONJ  compared  to  healthy  groups[215,  216],  but  has  thus  far  not  been  
investigated  for  DRONJ.  The  bone  structures  also  appeared  more  unorganized  in  
MRONJ  disease  variants  with  the  presence  of  higher  numbers  of  bone  reversal  
lines  than  Osteoporosis  or  Healthy.  This  was  in  accordance  with  the  findings  of  
Kim  et  al.,  who  also  reported  evidence  of  increased  thick,  irregular  bone  reversal  
lines  and  immature  woven  bone  in  BRONJ.[217]  Previous  authors  have  
concluded  that  changes  in  bony  histomorphometrics  could  be  a  consequence  of  
the  prolonged  effects  of  antiresorptives  on  bone  metabolism  and  structure.[39,  
218]  
  
Haversian  canals  surround  blood  vessels  and  nerve  cells  throughout  the  bone.  
The  lamellae  are  concentric  layers  surrounding  the  canal  which  contain  
osteocytes  in  their  lacunae.  Osteocytes  communicate  with  each  other  and  the  
Haversian  canal  through  cytoplasmic  extensions  spanning  small  interconnecting  
canals  called  canaliculi.[219]  Osteocytes  control  osteoclast  and  osteoblast  
activity  by  monitoring  several  hundred  µm3  of  bone  via  dendrites  in  canaliculi  by  
means  of  mechanicosensation  and  mechanicotransduction.[216,  220]  They  are  
believed  to  detect  bone  stress  and  respond  by  producing  signals  such  as  nitric  
oxide  and  sclerostin  within  the  lacuno-­canalicular  network  to  initiate  bone  
formation  or  resorption  (Figure  36).[221-­223]  
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Figure  36.  Osteocyte  involvement  in  signaling  bone  damage.[224]  
  
  
Our  findings  lead  us  to  hypothesize  that  MRONJ,  and  in  particular  DRONJ,  could  
develop  by  means  of  a  limited  osteocyte  network  and  consequent  disturbed  and  
disorganized  bone  remodeling.  This  decrease  in  osteocyte  networks  could  be  
due  to  the  antiresorptive-­induced  over-­suppression  of  bone  turnover  and  
subsequent  over-­ossification  which  crowds  out  osteocytes.  Micro-­CT  results  
revealed  that  every  ONJ  variant  exhibited  a  lower  mean  percentage  of  medullary  
space  to  bone  compared  to  the  healthy  group.  Mixed  ONJ  (p  =  .033),  BPDN-­
exposed,  DRONJ,  BP-­exposed,  ORN,  BRONJ  also  exhibited  the  widest  
trabecular  width,  while  the  healthy  group  had  the  narrowest  trabecular  width.  
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Results  from  the  radiographic  study  also  indicated  that  cortical  and  cancellous  
bone  sclerosis  were  the  two  most  frequently  observed  radiographic  findings  in  
the  patient  population  affected  by  BRONJ,  DRONJ,  and  Mixed  ONJ,  along  with  
higher  numbers  of  patients  with  a  thickened  lamina  dura  surrounding  the  teeth.  
This  dense  trabecular  network  with  reduced  medullary  space  and  clinically  visibly  
sclerosing  bone  upon  radiographic  examination  could  be  an  indication  of  the  
mechanism  of  over-­ossification  leading  to  subsequent  osteocyte  apoptosis,  
supporting  the  theory  of  suppressed  bone  turnover  and  trabecular  thickening.    
  
It  has  been  demonstrated  that  denosumab  suppresses  bone  remodeling  even  
more  than  alendronate  by  directly  affecting  bone  microarchitecture.[225,  226]  
Decreased  bone  turnover  upon  micro-­CT  with  reduced  porosity  and  increased  
bone  mineral  density  was  documented  in  postmenopausal  women  treated  with  
denosumab  for  osteoporosis  in  the  FREEDOM  study.[227]  Similar  
histomorphometric  indices  of  increased  total  bone  mineral  density,  remodelling  
suppression,  and  microarchitectural  changes  in  cortical  bone  was  observed  with  
denosumab  when  compared  to  alendronate-­treated  patients.[228]  A  mouse  
model  of  fracture  healing  compared  bone  volume  and  bone  mineral  density  
between  alendronate  and  denosumab,  and  found  that  denosumab-­treated  bone  
exhibited  a  more  dense  appearance  on  micro-­CT  with  almost  no  distinct  
trabeculae  formed.[229]  A  bone  scintigraphy  study  reported  no  differences  in  
bone  turnover  of  the  mandible  compared  to  other  skeletal  sites  in  patients  
receiving  BPs  and  denosumab.[230]  However,  since  the  jaw  bone  has  been  
recognized  to  have  a  higher  bone  turnover  than  other  skeletal  sites  to  begin  
with[22,  214,  231],  likely  due  to  large  forces  of  mastication  or  the  need  to  clear  
numerous  oral  bacteria[109],  a  comparable  turnover  rate  to  the  femur  would  
indeed  indicate  decreased  bone  remodelling  in  the  mandible.  Osteopetrosis  due  
to  the  genetic  absence  of  RANKL  has  been  previously  described[232],  with  a  
difference  in  skeletal  site  turnover  due  to  osteoclast  heterogeneity.[233]  
Experiments  with  transgenic  
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subsequent  suppression  may  be  skeletal  site-­specific,  as  normalizing  osteoclast  
function  in  long  bones  did  not  produce  a  similar  result  in  the  jaws.[233]  
  
Rapid  over-­ossification  could  cause  bone  fatigue  and  microdamage  in  bone  with  
atypical  fragility.[126]  Anastasilakis  et  al.  reported  that  patients  on  long-­term  
denosumab  exhibited  a  “frozen  bone”  phenomenon  with  increased  risk  of  atypical  
fragility  possibly  due  to  the  over-­suppression  of  bone  turnover.[126]  Excessive  
loading  of  the  cortical  bone  induces  the  formation  of  microcracks;;  these  areas  of  
damaged  bone  are  subsequently  resorbed  with  evidence  of  osteocyte  apoptosis  
in  these  respective  regions.[234,  235]	  More  microfractures  have  been  identified  
by  scanning  electron  microscopy  in  MRONJ  bone  samples  compared  to  
osteomyelitis,  osteoradionecrosis,  and  osteoporosis.[236]  Continous  
microtrauma  from  the  daily  forces  of  jaw  movement  could  further  exacerbate  
osteocyte  death  in  fragile  bone,  and  when  combined  with  a  lack  of  adequate  
bone  remodeling,  could  lead  to  necrosis.[32]    
  
It  has  been  also  suggested  that  over-­ossification  leading  to  the  expansion  of  the  
bone  compartment  could  result  in  ischemic-­necrotic  changes  despite  the  
absence  of  reduced  angiogenesis  following  antiresorptive  therapy.[39]  Favia  et  
al.  noted  that  the  histomorphometric  features  seen  in  their  study  of  BRONJ  
patients  was  similar  to  what  occurs  in  osteopetrosis,  where  the  metabolic  
demand  of  bone  would  increase  but  would  not  be  compensated  by  a  concurrent  
and  adequate  increase  of  blood  supply.[39]  This  could  also  be  due  to  a  
disturbance  of  the  osteocyte  system,  where  a  decreased  density  of  osteocytes  
and  their  corresponding  sensory  and  vascular  channels  could  imply  that  the  
nutrition  for  bone  would  have  a  longer  distance  to  travel,  resulting  in  silently  
expanding  areas  of  matrix  necrosis.  This  could  provide  a  compatible  picture  
connecting  our  observations  of  overossified  bone  and  decreased  number  of  
osteocytes  coinciding  with  unaffected  markers  of  angiogenesis  (VEGF  and  IL-­8)  
and  intact  Haversian  canals.  The  bone  could  be  increasing  in  density,  but  not  
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provided  with  enough  nutrition  via  blood  supply  to  compensate  for  this  increased  
metabolic  demand,  resulting  in  ischemic-­necrotic  changes.  This  could  also  
explain  why  other  anti-­angiogenic  agents  such  as  bevacizumab  have  been  seen  
to  exacerbate  these  effects  when  combined  with  antiresorptives.[7,  108]    
  
Antiresorptives  have  furthermore  been  implicated  in  having  a  direct  toxic  effect  
on  osteocytes[237],  since  it  has  been  demonstrated  that  BPs  can  become  
embedded  in  the  osteocyte  lacunae.[238]  Previous  studies  have  revealed  that  
BPs  at  low  concentrations  inhibit  osteocyte  apoptosis.[239,  240]  However,  at  
high  concentrations  osteocyte  cell  death  is  increased.[241]  Allen  et  al.  propose  
that  high  concentrations  of  antiresorptive  medications  may  accumulate  near  the  
osteocyte  and  induce  apoptosis.[28]  Osteocytes  exposed  to  zoledronate  have  
also  exhibited  more  variable  distribution  patterns  in  cortical  bone  which  increased  
with  drug  exposure  time.[242]  A  reduction  in  the  number  of  osteocytes  was  
directly  related  to  the  increase  in  distance  from  bone  channels.[242]  This  
increased  heterogeneity  in  osteocyte  distribution  in  the  matrix,  with  longer  cell-­to-­
cell  distance,  could  affect  mechanotransduction  and  fluid  flow  and  decrease  the  
functional  adaptability  of  the  bone.[243]  The  distribution  of  osteocytes  is  normally  
optimized  in  terms  of  transport  costs  of  nutrients  and  cellular  signals  between  
cells  and  blood  vessels.[244]  A  dense  and  well-­organized  osteocyte  network  is  
considered  essential  to  facilitate  fluid  flow  and  diffusion  of  ions,  hormones,  and  
signaling  molecules.[245,  246]  A  disruption  in  the  system  could  lead  to  a  low  
quality  of  the  bone  material,  as  evidenced  by  the  irregular  bone  reversal  lines  
and  disorganized  structural  appearance  of  our  histologic  samples.  
  
As  antiresorptives  are  capable  of  inducing  an  inflammatory  reaction  as  discussed  
in  previous  sections,  TNF-­α,  IL-­1β,  and  high  oxidative  stress  have  also  been  
demonstrated  to  modulate  an  increase  in  osteocyte  apoptosis.[247-­250]  We  
observed  a  marked  increase  of  TNF  and  IL-­1β  in  our  experiments  with  gingival  
fibroblasts  and  in  co-­culture  with  THP-­1  cells  with  high  concentrations  of  
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zoledronate,  denosumab,  the  combination  of  zoledronate  and  denosumab,  
clodronate,  and  ibandronate.  The  formation  of  apoptotic  bodies  in  osteocytes  
could  also  stimulate  the  recruitment  and  activation  of  macrophages  and  




4.6  Scientific  relevance  for  the  dental  practioner  
As  the  current  patient  population  ages,  more  patients  may  be  compromised  by  
osteoporosis  and  oncologic  tumors  and  treated  with  antiresorptive  medications.  
The  fields  of  oral  and  maxillofacial  surgery,  oral  medicine,  and  dentistry  will  be  
confronted  with  a  growing  number  of  patients  presenting  with  bone  necrosis  of  
the  facial  skeleton.  The  role  of  soft  tissue  in  the  pathogenesis  of  MRONJ  is  to  
date  particularly  not  well  defined,  and  may  be  crucial  in  discerning  how  the  
underlying  bone  is  exposed,  infected,  and  unable  to  heal.    
  
Our  experiments  demonstrated  that  assumed  high  and  medium  concentrations  of  
BPs  led  to  gingival  fibroblast  cell  death,  which  may  indicate  clinically  that  certain  
dosages  of  antiresorptives  interfere  with  soft  tissue  coverage  of  the  jaw  bones  
with  risk  of  bone  exposure.  This  has  also  been  demonstrated  with  oral  
keratinocyte  cells  and  BPs  at  concentrations  between  5  and  100  µM[96],  
strengthening  the  theory  of  a  combined  intrinsic  and  extrinsic  pathway  of  toxicity  
which  includes  soft  tissue  as  a  key  component  of  MRONJ  pathogenesis.[41]  The  
oral  epithelium  is  unique  in  that  no  fat,  fascia,  or  muscle  layers  buffer  it  from  the  
underlying  bone.[252]  Since  fibroblasts  and  cells  of  the  immune  system  can  also  
express  RANKL,  OPG,  and  IL-­6,  disturbance  of  these  cells  could  result  in  
disruption  of  the  mucosal  layer,  bacterial  infiltration,  and  affected  bone  
metabolism  leading  to  osteolysis.    
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We  also  observed  that  the  risk  of  soft  tissue  damage  was  influenced  by  the  
bacterial  challenge  simulated  by  P.  gingivalis  LPS  exposure.  A  bacterial  
challenge  such  as  periodontitis  has  been  associated  with  risk  of  MRONJ.[187,  
253]  Since  necrotic  bone  lesions  have  been  reported  to  contain  mainly  anerobic  
bacteria  representative  of  the  microflora  found  in  destructive  periodontitis,  dental  
practioners  should  consider  intensified  periodontitis  control  and  treatment  in  
antiresorptive-­exposed  patients.[187,  254]  Sedghizadeh  et  al.  detected  many  
common  periodontal  pathogens  within  biofilms  of  bone  affected  with  BRONJ,  
including  species  from  Fusobacterium,  bacillus,  actinomyces,  staphylococcus,  
streptococcus,  Selenomonas,  Treponema,  and  spirochetes.[254]  Hallmer  et  al.  
found  periodontal  pathogens  in  all  necrotic  jaw  samples  from  patients  affected  
with  both  BRONJ  and  DRONJ,  including  P.  gingivalis,  Tannerella  forsythia,  and  
Treponema  denticola,  which  have  been  demonstrated  to  cause  high  levels  of  
bone  resorption  in  vitro.  [253,  255,  256]  Destructive  periodontitis  is  associated  
with  a  T  helper  immune  response,  with  a  particularly  strong  stimulus  from  P.  
gingivalis  and  activation  of  RANKL-­induced  osteoclasts.  Previous  research  has  
indicated  that  patients  treated  with  BPs  exhibit  more  P.  gingivalis  species  in  
necrotic  specimens  than  the  patients  treated  with  denosumab,  suggesting  a  more  
active  role  of  BPs  in  inducing  an  optimal  environment  for  periopathogenic  
bacteria.[253]    
  
In  our  clinical  studies,  we  observed  that  dental  prostheses-­induced  pressure  
sores  were  often  the  precipitating  event  before  the  presentation  of  an  
osteonecrotic  lesion.  The  severity  and  accompanied  healing  complications  of  
prostheses  pressure  sores  could  be  explained  by  our  laboratory  results  with  
evidence  of  HGF  apoptosis.  Soft  tissue  affected  by  antiresorptives  may  be  more  
prone  to  breakdown  especially  when  accompanied  by  prolonged  mechanical  
pressure  from  prosthetic  devices.  Pressure  sores  are  a  common  phenomenon  
observed  with  dental  prostheses,  and  a  growing  body  of  evidence  points  to  
weight-­bearing  areas  of  soft  tissue[257]  as  a  risk  factor  which  influences  the  
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prognosis[258]  of  MRONJ.[259-­261]  Among  21  MRONJ  cases,  Niibe  et  al.  
observed  a  statistically  significant  difference  between  patients  with  removable  
dentures  and  those  with  no  prosthesis.[120]  It  may  be  prudent  for  dental  
practioners  to  remain  just  as  vigilant  for  the  risk  of  MRONJ  in  pressure-­bearing  
areas  of  dental  prostheses  as  with  direct  trauma  from  extractions  or  dental  
surgery.    
  
Additionally,  we  found  that  the  soft  tissue  may  be  inherently  at  risk  for  damage  by  
antiresorptives  even  without  invasive  mechanical  manipulation  such  as  dental  
extraction  or  local  surgery.  HGFs  were  seen  to  undergo  cell  death  even  without  
an  inflicted  wound  in  our  experiments.  Practioners  should  be  aware  of  the  risk  of  
MRONJ  even  in  patients  not  receiving  local  surgical  procedures.  This  could  
explain  our  clinical  cases  of  spontaneous  instances  of  MRONJ,  which  
predominantly  occur  where  the  mucosal  layer  is  particularly  thin.[93]  
Spontaneous  incidences  of  necrosis  has  been  reported  in  MRONJ  patients  to  be  
as  high  as  36%[261]  and  42%.[262]  Vescovi  et  al.  reported  approximately  32%  of  
untriggered  cases  in  a  cohort  of  567  BRONJ  patients.[263]  Spontanenous  cases  
have  ranged  from  mild  to  severe[264,  265],  and  antiresorptive  toxicity  to  the  
fibroblast  layer  could  be  implicated  in  the  development  of  this  complication.      
  
Reported  radiologic  findings  in  the  BRONJ  literature  have  included  cortical  
surface  irregularities,  persistent  extraction  sockets,  sequestration,  lytic  or  
radiolucent  changes,  and  an  increase  in  sclerosis  with  progressing  disease  
severity.[82,  84]  To  date,  radiographic  changes  in  DRONJ  have  not  been  
addressed  beyond  case  reports  in  literature.  Our	  analysis  of  all  available  
radiographic  images  revealed  that  dental  practioners  can  expect  osteosclerosis,  
cortical  bone  erosion,  and  persistent  extraction  sockets  as  the  most  common  
radiographic  signs  of  MRONJ.  Other  studies  have  also  noted  that  osteosclerosis  
was  frequently  observed  in  all  stages  of  BRONJ,  which  corresponded  to  our  
proposed  mechanism  of  over-­ossification  and  subsequently  reduced  osteocyte  
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network  from  the  histologic  results.[176,  266]  Similar  radiographic  features  of  
cortical  thickening  have  been  reported  with  osteopetrosis,  with  clinical  findings  of  
brittle  bone  susceptible  to  infection.[267,  268]  Focal  or  diffuse  osteosclerosis  was  
a  consistent  finding  in  patients  with  stage  0  MRONJ  without  exposed  bone  in  the  
clinically  symptomatic  area.[269]  We  also  noted  evidence  of  osteosclerosis  
prominent  in  areas  of  necrosis,  frequently  with  extension  beyond  the  lesion.  
However,  we  did  not  find  any  differences  that  would  allow  us  to  differentiate  
BRONJ,  DRONJ,  and  Mixed  ONJ  upon  radiologic  exam.  There  were  also  no  
obvious  differences  in  radiographic  findings  with  regard  to  antiresorptive  type,  
MRONJ  disease  variant,  presence  of  pain,  and  healing.    
  
CBCT  was  more  effective  in  the  visualization  of  bony  fistula,  fracture,  and  the  
extent  of  the  sequestrum  compared  to  CT,  and  also  detected  18.4%  more  
findings  than  panoramic  radiograph  in  intraindividual  comparisons  of  
simultaneous  panoramic  radiograph  and  CBCT  imaging  studies.  CBCT  was  
particularly  superior  for  DRONJ  patients  with  poor  healing  but  minimal  
radiographic  signs  upon  panoramic  radiograph  imaging,  which  did  not  
demonstrate  the  extent  of  the  lesion.  CT  was  helpful  for  visualizing  maxillary  
sinus  involvement  and  lymph  node  involvement.  However,  radiographic  signs  
observed  on  CT  and  MRI  have  been  reported  to  be  non-­specific  for  the  
disease.[270]  Furthermore,  though  they  exceeded  panoramic  radiographs  in  the  
detectability  of  BRONJ  lesions,  CT  and  MRI  were  reported  to  underestimate  the  
extent  of  the  intra-­operative  lesion  within  a  range  of  50%.[85]  Panoramic  
radiograph  was  useful  for  visualizing  sclerosis,  though  did  not  provide  as  much  
detail  as  3D  imaging  modalities.  Bianchi  et  al.  found  that  CBCT  was  superior  
than  panoramic  radiograph  in  detecting  six  common  radiologic  signs,  since  
panoramic  radiograph  often  missed  the  diagnosis  of  sequestration.[83]	  CBCT  
could  be  recommended  for  all  MRONJ  variants,  particularly  in  cases  where  
panoramic  radiograph  does  not  demonstrate  the  extent  of  the  lesion  per  clinical  
judgement.    
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We  observed  that  patients  who  receive  operative  intervention  were  more  likely  to  
have  improved  outcomes  upon  both  clinical  exam  and  evaluation  of  radiographic  
signs.  Patients  who  were  operated  on  were  more  likely  to  exhibit  improved  or  
stable  sequestrum  lesions  upon  radiographic  exam;;  this  remained  statistically  
significant  even  when  controlling  for  age  and  presence  of  pain.  Patients  in  the  
operative  group  were  also  more  likely  to  have  improved  or  stable  bony  fistulas  
observed  on  radiographs  compared  to  non-­operatively  managed  patients,  which  
remained  statistically  significant  when  controlling  for  age.  Operated  patients  were  
also  more  likely  to  be  healed  compared  to  patients  who  received  non-­operative  
treatment,  regardless  of  controlling  for  MRONJ  stage,  pain,  and  number  of  
medication  doses.  Ruggiero  and  Kohn  reported  that  operative  management  such  
as  alveolectomy,  marginal  resection,  or  segmental  resection  was  28  times  more  
likely  to  have  an  improved  outcome  compared  to  non-­operative  management  in  a  
retrospective  study  of  337  patients.[262]  Positive  outcomes  and  cure  rates  were  
also  reported  in  other  investigations  for  patients  treated  operatively  for  
MRONJ[271-­274];;  however,  details  regarding  radiographic  changes  were  sparse.    
  
  
4.7  Study  limitations  
A  major  limitation  of  our  laboratory  experiments  with  HGFs  was  that  we  were  not  
able  to  simulate  the  oral  mucosa  as  a  whole  in  vitro.  Although  we  attempted  to  
account  for  the  interactions  of  gingival  fibroblasts  with  a  macrophagic  cell  line  of  
the  local  immune  system,  it  would  be  ideal  to  be  able  to  observe  the  effects  of  
the  cellular  composition  of  the  entire  epithelium  and  connective  tissue  in  
response  to  antiresorptive  medications,  along  with  interactions  with  the  
underlying  bone.  Ravosa  et  al.  investigated  both  oral  keratinocytes  and  fibroblast  
cells  lines  in  a  study  with  various  concentrations  of  zoledronate  and  found  that  
oral  fibroblasts  were  more  susceptible  to  BPs  than  epithelial  cells.[103]  Scheper  
et  al.  observed  fibroblast  growth  inhibition  at  low  BP  concentrations  which  
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affected  keratinocytes  with  increasing  concentration.[45]  A  3-­dimensional  oral  
mucosal  wound-­healing  model  was  established  using  a  mixture  of  fibroblasts  in  a  
collagen  stromal  bed  with  keratinocytes  plated  on  top  days  later.[97]  This  
transwell  containing  the  fibroblast/keratinocyte  bed  was  air-­lifted  for  the  
administration  of  BP  and  impaired  proliferation  and  migration  of  oral  mucosal  
cells  was  observed.[275]  A  more  comprehensive  model  including  cells  of  the  
immune  system,  endothelial  network,  and  underlying  bone  would  be  ideal  to  
elucidate  the  exact  interactions  in  the  pathogenic  process  of  MRONJ.  This  could  
be  considered  with  the  use  of  hydroxyapatite  scaffolds  underneath  the  above-­
mentioned  3-­dimensional  oral  mucosal  model.  
  
The  oncologic  nature  of  the  THP-­1  cell  used  in  co-­culture  may  also  have  some  
limitations  with  respect  to  their  immortalized  character.[48]  This  may  have  
contributed  to  fluctuations  in  measurements  of  the  co-­culture,  and  future  studies  
may  consider  isolated  human  monocytes.  Future  research  would  also  benefit  
from  expanded  analyses  of  additional  cytokines  associated  with  hard  and  soft  
tissue  homeostasis,  including  TGF-­β,  matrix  metalloproteinases  (MMPs),  
CXCL12,  and  CXCR4,  with  investigation  of  Smad-­dependent  signaling  pathway  
inhibition.  Further  analyses  to  clarify  the  influence  of  IL-­6  is  recommended.  
  
Our  histologic  study  was  affected  by  small  sample  sizes  of  less  common  
diseases  such  as  DRONJ,  Mixed  ONJ,  and  bone  exposed  to  both  BPs  and  
denosumab.  This  was  because  our  patient  cohort,  unlike  other  case  series,  
included  patients  treated  with  denosumab  not  previously  exposed  to  other  
antiresorptives  in  order  to  isolate  the  behavior  of  agent-­specific  osteonecrosis  
and  eliminate  confounding  histories.  Bone  specimens  in  general  were  
characterized  by  a  high  heterogeneity  and  sometimes  poor  sample  quality.  
Histomorphometric  analyses  with  micro-­CT  could  have  also  been  influenced  
according  to  which  views  were  selected  at  random  for  the  measurement  of  
trabecular  width  or  the  percentage  of  medullary  space  to  bone.	  A  dearth  of  long-­
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term  follow-­up  data  limited  our  attempt  to  describe  changes  in  radiographic  signs  
over  time.  Due  to  the  retrospective  nature  of  both  clinical  investigations,  we  were  
unable  to  perform  more  comprehensive  time-­to-­event  statistical  analyses.  
  
  
4.8  Future  areas  of  research  
Newer  cases  of  MRONJ  are  being  reported  with  other  medication  classes[18-­20]  
used   in   cancer   therapy,   and   the  use  of   potent   nitrogen-­containing  BPs   to   treat  
osteoporosis  is  increasing  in  practice.[276]  Therefore,  clinicians  and  researchers  
may  expect  to  see  an  increase  in  the  incidence  of  MRONJ.  Our  next  project  will  
expand  experiments  with  HGFs  to  TKIs,  mTOR  inhibitors,  and  VEGF   inhibitors,  
alone  and  in  combination  with  BPs.  Recently,  De  Colli  et  al.  reported  that  newly  
synthesized  sulfonamide-­containing  BPs  did  not  affect  HGF  viability  and  adhesion  
when   compared   to   zoledronate.   Future   studies   could   also   be   directed   to  





MRONJ  is  a  disease  growing  in  prevalence  for  which  the  pathogenesis  remains  
unclear.  We  propose  that  the  etiology  of  MRONJ  could  be  attributed  to  a  
multifactorial  process  involving  both  the  hard  and  soft  tissues  of  the  maxillo-­
mandibular  region  (Figure  37).  This  could  include  over-­suppressed  bone  turnover  
as  a  mechanism  combined  with  soft  tissue  toxicity,  immune  dysfunction,  
disturbed  bone  resorption,  and  a  bacterial  presence,  which  could  help  explain  
why  these  lesions  are  not  present  elsewhere  in  the  skeleton.  The  anatomical  
features  of  thin  oral  mucosa  with  no  fat  or  fascia  separating  it  from  the  underlying  
bone  in  combination  with  the  sustained  forces  of  daily  jaw  movement  and  
constant  bacterial  exposure  make  the  oral  cavity  a  unique  location  for  the  
occurrence  of  MRONJ.  We  found  that  antiresorptives  resulted  in  HGF  death  and  
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delayed  wound  healing,  which  was  medication  dose-­dependent.  There  was  also  
evidence  of  an  alteration  of  the  immune  response,  in  particularly  in  co-­culture  
with  THP-­1  cells,  which  demonstrated  an  excessive  production  of  IL-­1β  and  TNF  
and  suppressed  levels  of  IL-­6  in  high  concentrations  of  nitrogen-­containing  BPs.  
This  was  exacerbated  by  bacterial  LPS,  which  has  been  demonstrated  along  with  
IL-­1β  and  TNF  to  activate  the  inflammatory  response  and  cause  bone  
resorption.[62,  139,  190]  
  
Osteoclast   inhibition   was   noted   in   gingival   fibroblasts,   but   bone   specimens  
exhibited  cells  positively  stained  for  RANKL  and  TRAP  for  BRONJ  and  Mixed  ONJ  
disease  groups.  We  suggest  this  could  be  due  to  an  M2  to  M1  pro-­inflammatory  
cytokine   profile   shift   resulting   in   dysfunctional   and   destructive   osteoclastic-­
macrophagic  cells  unable  to  resolve  a  continued  process  of  inflammation  and  bone  
resorption.  The  alveolar  process  is  unique  from  other  skeletal  sites  as  it  endures  
significant  mechanical   force  adjacent   to  a   thin  epithelium  constantly  exposed  to  
bacterial  agents.[231]  It  could  also  be  possible  that  bacterial   invasion  combined  
with   a   dysfunctional   immune   response   could   give   rise   to   a   cell   type   in   the  
macrophage-­osteoclast  continuum  with  the  capability  to  resorb  functional  and  vital  
bone,  accounting  for  the  presence  of  sequestra  in  MRONJ.  
  
We  suggest  that  a  suppressed  normal  bone  turnover  could  result  in  over-­
ossification  of  bone  and  crowding  out  of  osteocytes  leading  to  a  decreased  
osteocyte  network  unable  to  maintain  bone  homeostasis.  A  consequent  
increased  metabolic  demand  where  nutrition  for  bone  would  have  a  longer  
distance  to  travel  could  generate  silently  expanding  areas  of  matrix  necrosis.  We  
did  not  observe  any  evidence  of  inhibited  angiogenesis  in  both  the  in  vitro  and  
histologic  studies.  This  could  be  a  compensatory  mechanism  of  the  vasculature  
to  respond  to  an  increasing  metabolic  demand  due  to  a  dearth  of  osteocyte  
networks.  The  destructive  cycle  could  be  further  perpetuated  when  vascular  flow  
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to  the  affected  regions  could  function  in  allowing  more  antiresorptives  to  enter  the  
bone  and  extracellular  fluid.  
  
Our  results  also  lead  us  to  believe  that  the  pathogenesis  of  MRONJ  due  to  BPs  
and  denosumab  could  develop  via  differing  mechanisms  of  action  resulting  in  
similar  clinical  appearances  of  necrosis.  BRONJ  lesions  appear  to  be  affected  
more  by  soft  tissue  toxicity  and  an  inability  to  activate  the  acquired  immune  
response  resulting  in  a  dysfunctional  macrophagic-­osteoclastic  cell-­induced  bone  
destruction.  DRONJ  seems  to  be  more  influenced  by  over-­ossification  and  a  
decreased  osteocyte  network  due  to  its  RANKL-­inhibiting  pharmacologic  action,  
which  could  lead  to  ischemic-­necrotic  changes  seen  in  necrosis.  When  combined  
with  mechanical  trauma,  infection,  and  further  immunosuppression  from  
concurrent  therapies,  these  factors  may  lead  to  the  development  of  MRONJ.  
       
  
  
Figure  37.  Proposed  model  of  the  pathogenesis  of  medication-­related  
osteonecrosis  of  the  jaw  (MRONJ).  The  etiology  of  MRONJ  could  be  
attributed  to  a  multifactorial  process  involving  soft  tissue  toxicity,  
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mechanical  damage  and  surgical  trauma,  local  inflammation,  immune  
suppression  and  dysfunction,  infection  and  biofilm  alteration,  
dysfunctional  bone  resorption,  over-­ossification  and  a  limited  osteocyte  
network,  and  impaired  wound  healing  leading  to  necrotic  bone  exposure.  
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5  Summary  
Although  the  first   incidence  of  MRONJ  was  described  over  fifteen  years  ago,  to  
date   the  pathogenesis  of   the  disease   remains  unclear.  As  a   result,   there   is   no  
consensus  on  a  unified  treatment  or  prevention  protocol.  Treatment  of  MRONJ  is  
difficult  and  costly,  and  disease  sequela  can  include  pain,  infection,  inability  to  eat,  
extraoral  fistula,  and  pathologic  fracture,  all  of  which  significantly  impact  the  quality  
of  life  for  patients.  
  
Since  the  role  of  soft  tissue  in  the  pathogenesis  of  MRONJ  is  particularly  not  well  
defined,  this  doctoral  project  aimed  to  investigate  the  role  of  BPs  and  denosumab  
to  induce  or  inhibit  cell  death  and  inflammation  in  the  expression  patterns  of  HGFs,  
and  to  observe  the  influence  on  wound  healing  and  angiogenesis  in  response  to  
antiresorptive  therapy.  A  novel  real-­time   in  vitro  assay  was  performed  on  HGFs  
with  and  without   the  addition  of  bacterial  LPS  and  a  co-­culture  of  mononuclear  
cells   to   observe   the   effect   of   various   antiresorptives   (zoledronate,   ibandronate,  
alendronate,   clodronate,   denosumab,   and   combinations   of   zoledronate   and  
denosumab)   at   estimated   low,   middle,   and   high   concentrations   using   the  
xCelligence  system.  A  wound  healing  assay  was  also  performed,  and  gene  and  
protein  expression  was  analyzed  for  various  cytokines  and  mediators,  including  IL-­
1β,  IL-­6,  IL-­8,  VEGF,  TNF,  OPG,  and  RANKL.  
  
Retrospective  histologic  and  radiographic  studies  were  also  conducted  to  correlate  
the   altered   bone   structure   with   different   disease   variants   and   degree   of  
antiresorptive  exposure  in  in  vivo  studies  of  the  accompanying  hard  tissue.	  A  total  
of   158   bone   biopsies   were   collected   from   patients   with   various   infectious,  
inflammatory,   and   necrotic   jaw   diseases   and   stained  with  H&E,  RANKL,  OPG,  
TRAP,  toluidine  blue,  CD14,  and  CD68.	  Micro  CT  of  the  samples  were  additionally  
analyzed.	  Radiographic  records  of  37  MRONJ  patients  were  reviewed  for  imaging  
findings  before  and  after  disease  management.  Radiographic   signs  of   necrosis  
were  noted  in  MRONJ  disease  variants  and  imaging  techniques  were  compared  
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to  evaluate  the  correlation  of  the  clinical  presentation  and  outcomes  with  imaging  
findings  in  a  total  of  86  radiographic  studies.  
  
Our  results  revealed  that  higher  concentrations  of  antiresorptives  resulted  in  HGF  
cell  death  (zoledronate  50  µM  at  66.0  hours;;  alendronate  50  µM  at  64.0  hours;;  
ibandronate    50  µM  at  66.0  hours,  all  p  <  .05  compared  to  controls  at  90.4  hours)  
and  impaired  wound  healing  (clodronate  500  µM,  ibandronate  5  µM  and  50  µM,  
alendronate  50  µM,  zoledronate  5  µM  +  denosumab  10  µg/mL,  and  zoledronate  5  
µM).  These  effects  increased  with  the  introduction  of  bacterial  LPS  (aledronate  5  
µM  and  0.5  µM  additionally  affected,  p  <  .05)  and  in  co-­culture  with  a  mononuclear  
cell   line   (zoledronate   5   µM   and   zoledronate   5   µM   +   densumab   40   µg/mL  
additionally  affected,  p  <  .05).  There  were  also  signs  of  altered  immune  response,  
with  an  elevated  immune  reaction  and  possible  dysfunction  as  a  result  of  exposure  
to  antiresorptives.  Increased  levels  of  TNF  (443  gene  copies  of  zoledronate  50  µM  
with  LPS  and  2.66  gene  copies  of  denosumab  40  µg/mL  with  LPS  compared  to  0  
in  control),   IL-­8  (16.9  gene  copies  of  zoledronate  50  µM  with  LPS  compared   to  
0.007  gene  copies   in  control),   IL-­1β  (all  concentrations   increased,  p  <  .05),  and  
CD14  and  CD68  expression  (Mixed  ONJ  and  BRONJ  p  <  .001)    were  observed,  
perhaps  due  to  a  sustained  inflammatory  response,  while  an  IL-­6  response  was  
missing  for  high  concentrations  of  nitrogen-­containing  BPs  (all  p  <  .05),  which  may  
suggest  a  deficiency  in  the  shift  from  innate  to  acquired  immunity.  
  
Osteoclast   inhibition   was   noted   in   HGFs   which   demonstrated   an   increased  
expression   of   OPG   upon   exposure   to   zoledronate   (773   gene   copies)   and  
denosumab   (6.01   gene   copies)   compared   to   0.28   in   control,  with   low   levels   of  
RANKL.  However,  bone  specimens  exhibited  cells  positively  stained  for  RANKL  
(BRONJ  p  =  .021)  and  TRAP  (Mixed  ONJ  p  =  .002;;  BRONJ  p  <  .001;;  BP-­exposed  
p  =   .017).  There  was  no  evidence  of  an  anti-­angiogenic  effect  as  evidenced  by  
levels  of  VEGF  and  IL-­8  as  well  as  the  appearance  of  intact  Haversian  systems  in  
the  bone.  Upon  examination  of  the  bone  tissues  in  the  histologic  and  radiographic  
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study,  results  suggest  that  a  limited  osteocyte  network  (mean  number  of  osteocyte  
lacunae  per  µm2  in  DRONJ:  0.00026,  p  <  .05)  and  over-­ossification  of   the  bone  
(decreased  ratio  of  medullary  space  to  bone  p  <  .01  for  MRONJ  variants;;  increased  
trabecular  width  of  601.71  µm  in  Mixed  ONJ;;  p  =  .03;;  presence  of  sclerosis  upon  
radiographic   exam   in   92%  of  MRONJ   patients)   could   play   in   a   role   in   disease  
development.  Our  findings  lead  us  to  believe  that  the  precise  pathogenesis  could  
differ  based  on  whether  the  offending  agent  is  a  BP  or  denosumab,  which  still  may  
result  in  a  similar  appearance  of  necrosis.  From  our  clinical  studies,  patients  who  
received   operative   treatment   were   more   likely   to   exhibit   complete   healing  
compared  to  patients  who  received  non-­operative  management  (p  =  .001).  CBCT  
was   more   effective   to   visualize   bony   fistula,   fracture,   and   the   extent   of   the  
sequestrum   (68.2%   detectability)   compared   to   CT   (30.8%   detectability),   and  
detected   18.4%   more   findings   than   panoramic   radiograph   in   simultaneous  
comparisons.  
  
Many  of  these  findings  could  have  important  implications  for  researchers  
investigating  MRONJ  and  provide  clinical  relevance  for  treating  practitioners.  
This  was  the  first  investigation  of  HGFs  in  real-­time,  particularly  with  a  wide  
range  of  BP  concentrations.  To  study  the  effect  of  denosumab  on  HGFs,  as  well  
to  introduce  a  combination  of  zoledronate  and  denosumab  concentrations  to  
simulate  a  realistic  clinical  situation,  were  also  novel  research  objectives.  
Furthermore,  these  results  present  previously  unreported  details  on  the  features  
of  DRONJ,  Mixed  ONJ,  BP-­exposed  bone,  and  BP-­and  denosumab-­exposed  
bone,  particularly  as  we  were  able  to  identify  features  of  denosumab-­specific  
ONJ  without  influence  from  previous  BP  therapy.  
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7  German  summary  
  
Obwohl   die   Erstbeschreibung   der   Medikamenten-­assoziierten   Kiefernekrose  
(MRONJ)  nun  15  Jahre  vergangen  ist,  bleibt  die  Pathogenese  dieser  Erkrankung  
immer  noch  unklar.  Dementsprechend  gibt  es  keinen  einheitlichen  Konsens  über  
die  Behandlung  der  MRONJ  sowie  allgemein  akzeptierte  Präventionsprotokolle.  
Die   Behandlung   von   einer   MRONJ   ist   schwierig   und   kostspielig   und   die  
Spätkomplikationen   umfassen   Schmerzen,   Entzündungen,   mitunter   eine  
Unfähigkeit  zu  essen,  extraorale  Fisteln,  sowie  die  Möglichkeit  von  pathologischen  
Frakturen.   Diese   Erkrankung   führt   daher   zu   einer   deutlichen   Minderung   der  
Lebensqualität  der  betroffenen  Patienten.    
  
Da  die  Rolle  von  Weichgewebe   in  der  Pathogenese  von  MRONJ  unzureichend  
erforscht   ist,   untersucht   diese   Arbeit   die   Auswirkungen   von   Bisphosphonaten  
(BPs)  und  Denosumab  in  der  Induktion  und  Hemmung  von  einem  Zelltod  und  der  
Entzündung   an   Hand   von   Expressionsmustern   von   humanen   gingivalen  
Fibroblasten   (HGFs),   sowie  den  Einfluss  einer   antiresorptiven  Therapie   auf   die  
Wundheilung  und  die  Angiogenese.  Ein  In-­vitro-­Test  von  HGFs  mit  und  ohne  den  
Zusatz   von   bakteriellen   Lipopolysacchariden   (LPS)   und   einer   Co-­Kultur   von  
mononuklearen  Zellen  wurde  mittels   eines   xCellingence  Systems  durchgeführt,  
um   den   Effekt   von   verschiedenen   Antiresorptiva   (Zoledronat,   Ibandronat,  
Alendronat,   Clodronat,   Denosumab   und   Kombinationen   von   Zoledronat   und  
Denosumab)  bei  niedrigen,  mittleren,  und  hohen  Konzentrationen  zu  untersuchen.  
Ein  Wundheilungstest  (Wound  Scratch  Assay)  wurde  ebenfalls  durchgeführt  und  
eine   Gen-­   und   Proteinexpressionsanalyse   für   verschiedene   Zytokine   und  
Mediatoren   –   einschließlich	   Interleukin   1beta   (IL-­1β),   Interleukin   6   (IL-­6),  
Interleukin   8   (IL-­8),   vaskulärer   endothelialer   Wachstumsfaktor   (VEGF),  
Tumornekrosefaktor   (TNF),   Osteoprotegerin   (OPG)   und   Rezeptoraktivator   von  
nuklearem  Faktor  Kappa-­Β-­Ligand  (RANKL)  –  angewendet.    
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Eine  retrospektive  histologische  und  radiologische  Untersuchung  wurde  ebenfalls  
an   Knochenproben   durchgeführt,   um   die   Korrelationen   von   der   veränderten  
Knochenstrukturen  mit   verschiedenen  Krankheitsstadien  und  mit  dem  Grad  der  
antiresorptiven   Exposition   zu   analysieren.   Insgesamt   wurden   158  
Knochenbiopsien  von  Patienten  mit  verschiedenen  infektiösen,  entzündlichen  und  
nekrotischen   Kiefererkrankungen   mit   Hämatoxylin   und   Eosin   (H&E),   RANKL,  
OPG,   Tartrat-­resistenter   saurer   Phosphatase   (TRAP),   Toluidinblau,   CD14   und  
CD68  angefärbt  und  ausgewertet.   eine  Mikro-­Computertomographie   (µ-­CT)  der  
Proben   wurde   zusätzlich   durchgeführt.   Röntgenaufnahmen   von   37   MRONJ-­
Patienten  wurden  Bezug  auf  radiologische  Befunde  vor  und  nach  einer  Therapie  
und   im   Krankheitsverlauf   analysiert.   Radiologische   Anzeichen   von   Nekrose  
wurden   ausgewertet   und   verglichen.   Insgesamt   wurden   86  
Röntgenuntersuchungen  ausgewertet.  
  
Unsere  Ergebnisse  zeigten,  dass  höhere  Konzentrationen  von  Antiresorptiva  zu  
einem   Zelltod   der   HGF-­Zellen   führen   (Zoledronat   50   μM   bei   66   Stunden;;  
Alendronat  50  μM  bei  64  Stunden;;  Ibandronat  50  μM  bei  66  Stunden,  alle  p  <  0,05  
im   Vergleich   zu   Kontrollen   bei   90,4   Stunden),   sowie   die   Wundheilung  
beeinträchtigen   können   (Clodronat   500   μM,   Ibandronat   5   μM   und   50   μM,  
Alendronat  50  μM,  Zoledronat  5  μM  +  Denosumab  10  μg/ml  und  Zoledronat  5  μM).  
Diese   Effekte   steigerten   sich   unter   einer   Exposition   mit   bakteriellem   LPS  
(Alendronat  5  μM  und  0,5  μM;;  zusätzlich  beeinflusst,  p  <  0,05)  und  in  Co-­Kulturen  
mit  einer  mononukleären  Zellen  (THP-­1)  (Zoledronat  5  μM  und  Zoledronat  5  μM  +  
Denosumab  40  μg/mlM;;  zusätzlich  beeinflusst),  p  <  0,05).  Es  ergaben  sich  auch  
Anzeichen   einer   veränderten   Immunantwort   mit   einer   erhöhten   Immunreaktion  
und   einer   möglichen   Dysfunktion   als   Folge   der   Exposition   gegenüber  
Antiresorptiva.  Erhöhte  Spiegel  von  TNF  (443  Genkopien  von  Zoledronat  50  μM  
mit  LPS  und  2,66  Genkopien  von  Denosumab  40  μg/ml  mit  LPS  im  Vergleich  zu  0  
in  der  Kontrollgruppe),   IL-­8   (16,9  Genkopien  von  Zoledronat  50  μM  mit  LPS   im  
Vergleich  zu  0,007  Genkopien  in  der  Kontrollgruppe),  IL-­1β  (alle  Konzentrationen  
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erhöht,  p  <  0,05)  und  CD14  und  CD68-­Expression  (gemischte  Osteonekrose  des  
Kiefers  (ONJ)  und  Bisphosphonat-­assoziierte  Osteonekrose  des  Kiefers  (BRONJ)  
p   <   0,001)   wurden   beobachtet,   möglicherweise   aufgrund   einer   anhaltenden  
Entzündungsreaktion,   während   eine   IL-­6-­Reaktion   bei   hohen   Konzentrationen  
stickstoffhaltiger  BP  fehlte  (alle  p  <  0,05),  was  auf  einen  Defizit  eines  Wechsels  
von  der  angeborenen  zu  einer  erworbenen  Immunität  schließen  lässt.  
Eine   Osteoklasteninhibierung   wurde   durch   HGFs   vermutet,   die   eine   erhöhte  
Expression  von  OPG  bei  Exposition  gegenüber  Zoledronat  (773  Genkopien)  und  
Denosumab   (6.01  Genkopien)   im  Vergleich   zu   0,28   bei   der   Kontrollgruppe  mit  
niedrigen  RANKL-­Spiegeln  zeigten.  Knochenproben  zeigten  jedoch  positive  Zellen  
für  RANKL  (BRONJ  p  =  0,021)  und  TRAP  (gemischtes  ONJ  p  =  0,002;;  BRONJ  p  
<0,001;;  BP-­pausiert  p  =  0,017).  Es  gab  keinen  Hinweis  auf  einen  antiangiogenen  
Effekt,  was  durch  die  Spiegel  von  VEGF  und  IL-­8  sowie  das  Auftreten  von  intakten  
Havers'schen   Systemen   im   Knochen   vermutet   wurde.   Die   Analyse   der  
Knochengewebe   in  der  histologischen  und   radiologischen  Untersuchung  deutet  
darauf   hin,   dass   ein   begrenztes   Osteozyten-­Netzwerk   (mittlere   Anzahl   von  
Osteozyten-­Lakunen   pro   µm2   in   Denosumab-­assoziierter   Osteonekrose   des  
Kiefers   (DRONJ):   0,00026,   p   <   0,05)   und   eine  Ossifikation   von   dem   Knochen  
(erhöhtes  Verhältnis  von  Knochen  zu  Markraum  p  <  0,01  für  MRONJ-­Varianten;;  
erhöhte   Trabekelbreite   von   601,71   μm   bei   Mixed-­ONJ;;   p   =   0,03;;   und   das  
Vorhandensein  einer  Sklerose  nachgewiesen  in  einer  Röntgenuntersuchung  bei  
92%   der   MRONJ-­Patienten)   eine   Rolle   bei   der   Krankheitsentwicklung   spielen  
kann.  Unsere  Ergebnisse  lassen  darauf  schließen,  dass  die  genaue  Pathogenese  
davon   abhängen   könnte,   ob   das   Antiresorptivum   ein   BP   oder   Denosumab   ist,  
wobei   sich   klinisch   die  Nekrosen   ähneln.   Aus   unseren   klinischen  Studien   geht  
hervor,   dass   Patienten,   die   operativ   behandelt   wurden,   eine   bessere   Heilung  
zeigten  als  Patienten,  die  nicht  operativ  behandelt  wurden  (p  =  0,001).  Die  Cone-­
Beam-­CT-­Untersuchung   erlaubte   eine   bessere   Visualisierung   von   knöchernen  
fistelähnlichen  Strukturen,  von  Frakturen  und  der  bei  der  Größe  von  Sequestern  
(in  68,2%  der  Fälle)  im  Vergleich  zum  CT  (in  30,8%  der  Fälle),  und  zeigte  18,4%  
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häufiger   positive   Befunde   als   eine   Panorama-­Röntgenaufnahme   im   direktem  
Vergleich.  
  
Viele   dieser   Ergebnisse   könnten   wichtige   Implikationen   für   MRONJ-­Forschung  
haben  und  eine  klinische  Relevanz  für  die  Behandlung  bieten.  Dies  war  eine  der  
ersten   Untersuchungen   von   HGF-­Zellen   in   Echtzeit,   insbesondere   mit   einer  
breiten   Variabilität   von   BP-­Konzentrationen.   Die  Untersuchung   der   Auswirkung  
von   Denosumab   auf   HGF-­Zellen   sowie   die   Anwendung   einer   gleichzeitigen  
Kombination   von   Zoledronat-­   und   Denosumab   zur   Simulation   einer   realen  
klinischen   Situation,   waren   ebenfalls   neue   Forschungsziele.   Darüber   hinaus  
zeigen  diese  Ergebnisse  bisher  nicht  berichtete  Details   zu  den  Merkmalen  von  
DRONJ,   gemischtem   ONJ,   BP-­exponierten   sowie   BP-­   und   Denosumab-­
exponierten  Knochen,  insbesondere  da  einen  Einfluss  einer  Denosumabtherapie  
auch  ohne  einer  vorherigen  BP-­Therapie  nachweisen  konnten.  
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